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Summary 
Cerebral malaria is caused by a complicated series of immune reactions in the host, marked by 
inflammatory immune responses, margination of leukocytes and parasitized erythrocytes in 
cerebral vessels leading to breakdown of the blood-brain-barrier. Studies of the immune 
responses that lead to human cerebral malaria are limited since patients typically present once 
symptoms have commenced. Along with ethical considerations, this has led to the 
immunopathogenesis of cerebral malaria being studied in the rodent model. Such studies have 
generally overlooked the very early stage of infection, during which the malaria parasite invades 
the liver, despite some evidence that early immune responses and intrahepatic attenuated 
infections, such as caused by the RTS, S vaccine, play a role in preventing cerebral pathology.  
 
This thesis describes the development of a model that attenuates infection at a very early stage 
prior to the onset of blood infection by the subtherapeutic administration of isopentaquine, an 
8-aminoquinoline. Such chemical attenuation of the parasite at the very early, clinically silent liver 
stage suppresses parasite development, delays the time until parasites establish blood-stage 
infection and provokes an altered host immune response, altering immunopathogenesis and 
protecting from cerebral disease. This early response is a pro-inflammatory, cell-mediated one 
with increased T-cell activation in liver and spleen, elevated numbers of effector T cells, 
cytokine-secreting T cells and proliferating, multifunctional T cells producing pro-inflammatory 
cytokines. The response destabilizes the usual series of events that leads to cerebral pathology, 
by downregulating inflammatory responses and T-cell activation at late infection. Dendritic cell 
numbers, T-cell activation and infiltration of CD8+ T cells to the brain are decreased in later 
infection, mediated by the anti-inflammatory cytokine IL-10. 
 
These data indicate that liver-stage-directed early immune responses can moderate the overall 
downstream host immune response and modulate severe malaria outcome. Strikingly, CD8+ T 
cells isolated from the spleen as early as day 2 post infection are responsible for protection. 
Protection can be transferred to naïve animals by adoptive transfer of lymphocytes from the 
spleen at very early infection, but not when CD8+ T cells are depleted.  
 
The reliance of this phenotype on CD8+ T cells and the transferability of protection are of 
particular interest, especially since these cells are isolated so early on in infection. Neither 
attenuated infections or early T cell responses have been studied in relation to cerebral pathology 
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before and this is the first evidence that they can influence the course of the downstream 
systemic immune response and alter cerebral pathology. This draws parallels with the RTS, S 
vaccine, which is designed to elicit strong CD8+ T cell responses against the parasite in the liver, 
and produces similar protection exclusively against severe malaria, including cerebral malaria.  
 
This work has larger implications in dissecting the complex sequence of inter-related events that 
form the immunological basis of human cerebral (malaria) pathology and uncovers a relationship 
in both localization and timing of anti-parasitic T-cell responses involved in the 
immunopathogenesis of cerebral malaria, presenting an insight into the potential role of the pre-
erythrocytic response in tempering downstream cerebral immunopathogenesis. These data 
support the notion that Th1 cellular responses represent a kill or cure response to Plasmodium that 
must be tightly controlled in both a spatially and temporally specific manner. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  VIII 
Zusammenfassung 
Die zerebrale Malaria wird durch eine komplexe Abfolge von Immunreaktionen im Wirt 
verursacht. Kennzeichnend sind dabei pro-inflammatorische Immunantworten und die 
Margination von Leukozyten sowie infizierter Erythrozyten an die Hirngefäße, was schließlich zu 
einem Zusammenbruch der Blut-Hirn-Schranke führt. Genauere Untersuchungen der 
Immunantworten, die im Menschen zur zerebralen Malaria führen, werden jedoch dadurch 
erschwert, dass betroffene Personen in der Regel erst bei fortgeschrittener Symptomatik einen 
Arzt aufsuchen. Einhergehend mit ethischen Überlegungen hat dies dazu geführt, dass es 
sinnvoll ist, die Immunpathogenese der zerebralen Malaria im Tiermodell zu untersuchen. Einige 
solcher Tiermodellstudien haben Hinweise darauf gegeben, dass gerade relativ frühe 
Immunantworten oder auch abgeschwächte intrahepatische Infektionen wie z.B. durch den RTS, 
S Impfstoff hervorgerufen eine zentrale Rolle bei der Prävention einer zerebralen Pathologie 
spielen. Dennoch wurde bei bisherigen Studien in der Regel das sehr frühe Stadium der 
Infektion, nämlich der Befall der Leber, vernachlässigt und nicht als Interventions-Zeitpunkt in 
Betracht gezogen. 
Diese Arbeit beschreibt die Entwicklung eines Modells, in welchem die Malaria-Infektion in 
einem sehr frühen Stadium, noch vor dem Übertritt der Parasiten in das Blut, durch die 
subtherapeutische Verabreichung von Isopentaquin, einem 8-Aminochinolin, abgeschwächt 
wird. Durch diese chemische Attenuation des Parasiten während eines sehr frühen, klinisch 
asymptomatischen Leberstadiums kann die Entwicklung der Parasiten unterdrückt und die 
Zeitspanne bis zur Etablierung einer Blutstadieninfektion verlängert werden. Ferner wird eine 
veränderte Immunantwort ausgelöst, die wiederum zu einer Änderung der Immunpathogenese 
und zum Schutz vor zerebraler Malaria führt. Diese frühe Immunreaktion ist pro-
inflammatorischer Natur sowie zellvermittelt. Besondere Charakteristika sind hierbei eine 
erhöhte T-Zell-Aktivierung in der Leber und der Milz, eine erhöhte Anzahl von Effektor-T-
Zellen, Zytokin-produzierenden T-Zellen und proliferierenden, multi-funktionalen T-Zellen, die 
pro-inflammatorische Zytokine produzieren. 
Eine wie hier beschrieben ausgelöste Immunantwort bringt die übliche Kette von Ereignissen, 
die zur Ausprägung der zerebralen Malaria führen, aus dem Gleichgewicht. Insbesondere wird 
dies durch die Herunterregulierung von Entzündungsreaktionen und verzögerte T-Zell-
Aktivierung während der Infektion erreicht. In der späteren Phase der Infektion ist die Anzahl 
dendritischer Zellen, T-Zell-Aktivierung und die Infiltration von CD8+ T-Zellen in das Gehirn 
verringert. Dieser Effekt wird durch das anti-inflammatorische Zytokin IL-10 vermittelt. 
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Die hier präsentierten Daten belegen, dass frühe Immunantworten, die sich gegen das 
Leberstadium richten, die gesamte nachgeschaltete Immunantwort moderieren und die Folgen 
der schwerwiegenden Form der Malaria modulieren können. Hervorzuheben ist, dass CD8+ T-
Zellen, die zwei Tage nach der Infektion aus der Milz isoliert wurden, für den Schutz vor 
zerebraler Malaria verantwortlich sind. Der Schutz kann auf naive Tiere durch den adoptiven 
Transfer von während der frühen Phase der Infektion aus der Milz isolierten Lymphozyten 
übertragen werden. Dieser schützende Effekt wird durch die Depletion von CD8+ T-Zellen 
aufgehoben.  
 
Die Abhängigkeit dieses Phänotyps von CD8+ T-Zellen und die Übertragbarkeit des Schutzes 
sind von besonderem Interesse, insbesondere deshalb, weil diese Zellen in einer solch frühen 
Infektionsphase isoliert wurden. Bislang wurden weder attenuierte Infektionen noch frühe T-
Zell-Antworten in Bezug auf die Pathologie der zerebralen Malaria untersucht. Diese Arbeit 
liefert somit den ersten Beweis, dass diese den Verlauf der nachfolgenden systemischen 
Immunantwort beeinflussen können und die zerebrale Pathologie verändern. Diese Resultate 
weisen Parallelen mit der Wirkweise des RTS, S-Impfstoffes auf, der konstruiert wurde, um vor 
allem starke CD8+ T-Zell-Reaktionen gegen den Parasiten in der Leber hervorzurufen, und einen 
ähnlichen Schutz ausschließlich gegen zerebrale Malaria zeigt. 
 
Die vorliegende Arbeit hat größere Auswirkungen bezüglich einer detaillierten Aufklärung der 
komplexen Abfolge von miteinander verbundenen Ereignissen, die die immunologische 
Grundlage der zerebralen Malaria Pathologie bilden und deckt eine Beziehung zwischen der 
Lokalisation und dem Zeitpunkt der anti-parasitären T-Zell-Reaktionen auf, die in der 
Immunpathogenese der zerebralen Malaria beteiligt sind. Die Ergebnisse dieser Arbeit gewähren 
einen ersten Einblick in die potenzielle Rolle der prä-erythrozytären Immunantwort, die 
nachfolgende zerebrale Immunpathogenese zu mildern. Diese Daten unterstützen die 
Vorstellung, dass Th1-Antworten eine töten oder heilen Reaktion auf Plasmodium repräsentieren, die 
sowohl räumlich als auch zeitlich gezielt kontrolliert werden muss. 
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Chapter 1 
Introduction 
1.1 A Brief History of Malaria 
The term malaria originates from the mid-18th century Italian mala aria, meaning “bad air” [1]. 
Although intermittent fever is described in numerous historical texts of ancient Chinese, Indian 
and Greek origin dating from the third millennium BCE, [2] the first reliable historical account of 
malaria is attributed to Celsus in the first century CE [3]. Nonetheless, modern techniques in 
molecular biology and genetic anthropology have revealed that P. falciparum diverged from P. 
reichenowi some five to ten million years ago, parallel to the divergence of Homo from chimpanzees 
(fig 1.1) [2]. The most recent common ancestor of P. falciparum existed in tropical Africa some 
100,000 years ago [4] and the species underwent significant expansion 10,000 years ago upon the 
adoption and expansion of agriculture [5]. In contrast to P. falciparum, the strains P. ovale, P. vivax 
and P. malariae transferred laterally from primates to humans [2]. Malaria has had a significant 
influence on humanity, changing settlement patterns, agricultural systems and the age structures 
of early societies [6]. Malaria represents one of the strongest selective pressures on the history of 
the human genome [7] and is responsible for several diseases, including thalassemia, sickle-cell 
disease and glucose-6-phosphatase deficiency [8]. 
 
It was not until the end of the nineteenth century that significant advances were made in 
elucidating the true nature of malaria transmission. Within a relatively short period of time, 
parasites were discovered within the blood of a malaria patient by French army surgeon Charles 
Louis Alphonse Laveran [9] and shortly afterwards British medical officer Ronald Ross 
discovered that malaria is transmitted by mosquito bite [10]. 
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Treatment of malaria in the ancient world ranged from herbal preparations in China and Europe 
[11] to the administration of garlic in Ancient Egypt [12]. By far the most historically significant 
antimalarial is quinine, which was brought to Europe in the 17th century in the form of bark of 
the cinchona tree. By 1820 quinine was routinely extracted from the bark directly and is still 
administered today to treat cases of severe malaria [13-15], although a recent review of healthcare 
practises suggested that this should be stopped in favour of artesunate administration [16]. 
Chloroquine was synthesized en masse after world war two and displayed far greater potency than 
other synthetic antimalarials of its time [17]. For this reason, despite the emergence of 
chloroquine-resistant strains in the late 1950s, chloroquine remained the pre-eminent antimalarial 
compound for over 40 years. Indeed, the 20th century was marked by a decrease in malaria 
mortality due to drug and other public health interventions (fig 1.2). In the wake of chloroquine 
resistance, other antimalarials such as mefloquine, artemisinin derivatives, sulphadoxine-
pyrimethamine and atovquone-proguanil (Malarone®) were developed [13, 14]. Resistance 
commonly develops to antimalarials after 10-15 years and there are resistant strains to 
sulphadoxine-pyrimethamine, mefloquine and atavoquone, amongst others, although no clinically 
relevant artemisinin-resistant strain is reported to date [18]. 
 
1.2 The Global Health Burden of Malaria  
Over a century after the discovery of the causative agent of malaria, it still wreaks a devastating 
global health burden [19]. The number of deaths from malaria has increased by approximately 
20% since 1980 [20]. Today, there are approximately 250 million clinical cases of malaria annually 
with a mortality of 1.2 million individuals [20]. A recent study found that the number of malaria 
deaths has previously been underestimated, although control measures are steadily reducing the 
burden of disease, with a 34% reduction in mortality since 2004 [20]. The vast majority of deaths 
occur in sub-Saharan Africa, especially in children under the age of 5 (fig 1.3). The sheer numbers 
of deaths in this region dictate the rise and fall in global malaria statistics. Approximately 430,000 
Introduction  
 
 
3  
children younger than 5 in sub-Saharan Africa died of malaria in 2010, down from 1,000,000 in 
2004 but up from 377,000 in 1980  [20]. 
  
 
Figure 1.1 Phylogenetic tree for human Plasmodium (Carter and Mendis, 2002) [21] 
Deaths amongst individuals over the age of 5 show a similar trend. Outside of Africa, there has been a 
general decrease in malarial mortality from 199,000 in 1980 to 15,000 in 2010, amongst under-fives [20]. 
The substantial public health burden of malaria generates significant damage to the economy and 
productivity of affected regions. Malaria deaths are thought to account for 3% of the total world’s 
Disability Adjusted Life Years (DALYs) [22]. The impact on Africa is the most substantial, with malaria 
accounting for 10% of DALYs [22, 23] generating an annual cost of 12 billion USD (W.H.O. 2009). 
 
Public health efforts to combat malaria take the three-pronged approach of insecticide-treated 
bed nets, case management of malaria illness and preventative treatment. Despite a proven track 
record in reducing malarial transmission and pathology, they are not adequately controlling 
infection in sub-Saharan Africa [24, 25]. This is partially due to the emergence of drug-resistant 
strains but also the economic instability of affected countries and the lack of infrastructure 
required to instigate these public health measures en masse. 
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Figure 1.2 Historical perspective of malaria mortality in the last 100 years (Carter and Mendis 2002) 
[21] Europe and North America ( — ); the Caribbean and Central and South America (▪——▪); sub-
Saharan Africa (•——•); China and Northeast Asia (X—X); the Middle East, South Asia, and the Western 
Pacific ( —— ); and worldwide ( --- ) (Legend from Carter and Mendis, 2002). 
 
Artemisinin-based combination therapy, which results in rapid clearance of both asexual and 
sexual blood stages, in combination with a compound with a longer half-life, is partially reducing 
the effect of parasite resistant strains [26]. Intensive DDT treatment of bed nets and homesteads 
in the 1950s and 60s, although largely effective in eliminating malaria from the west, were 
discontinued amid resistance development in Anopheles mosquitoes and public health concerns 
[27-29]. To further combat the disease, investment in a combination of both traditional and new 
public health interventions is required. This may take the form of new drugs and larvicides, along 
with novel approaches such as transgenic “malaria-resistant” mosquitoes and vaccine design [24, 
29]. 
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1.3 Plasmodium  and its life cycle  
Malaria is caused by protozoan parasites of the Plasmodium genus. P. vivax, P. ovale, P. malariae, P. 
knowlesi and P. falciparum species specifically infect humans. The latter, P. falciparum, causes a 
severe form of malaria infection and is accountable for approximately 90% of deaths and 80% of 
human infections, with symptoms arising after approximately 6 to 14 days, including fever, 
vomiting, arthalgia, shivering, convulsions, haemoglobinuria and anaemia caused by haemolysis 
[30]. Symptoms peak approximately every 48 hours, marked by each successive release of 
merozoites from infected red blood cells [31].  
 
1.3.1 The pre-erythrocytic stage 
Plasmodium has a complex life cycle (fig 1.4) that utilizes the female Anopheles mosquito as a vector 
for transmission into the human bloodstream as the Anopheles mosquito takes a blood meal.  An 
infected Anopheles mosquito will pierces an individual’s skin to take a blood meal and release 
sporozoites from the saliva into the injection site. Upon injection of sporozoites into the skin, a 
significant proportion remain in the dermis while the rest enter the lymphatic circulation and are 
caught in the proximal lymph node where they present antigen to CD11c+ dendritic cells [32, 33]. 
Sporozoites cross the liver sinusoid by gliding along its surface and traverse kupffer cells [34-37]. 
Sporozoites migrate through several hepatocytes within the liver parenchyma before establishing 
a parasitophorous vacuole [38-40] derived from the host-cell membrane which is rapidly 
remodelled by parasite proteins [41]. The parasitophorous vacuole forms as the parasite migrates 
forward from an invagination in the cell plasma membrane [33], mediated via the hepatocyte  
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Figure 1.3 The distribution of malaria across the world in 2010. Colour scale represents “age 
standardized annual mean Plasmodium falciparum parasite rate in two to ten year olds” (Malaria Atlas 
Project) [42]. 
 
surface molecules, scavenger receptor BI and tetraspanin CD81 [43-46] and the parasite ligand 
TRAP [47, 48], although in the latter case, direct host-parasite interaction has not been 
biochemically demonstrated [33]. Once the parasitophorous vacuole is established, the parasite 
undergoes multiple nuclear divisions asexually and asymptomatically, then schizogony [49], which 
leads to the budding of merosomes from the infected hepatocyte [50, 51]. Merosomes are vesicles 
consisting of hundreds or thousands of merozoites [33]. They cross the sinusoidal barrier via an 
unknown mechanism and become trapped in the lung microvasculature, where they release their 
payload of merozoites directly into the lung capillaries [33, 52]. Merozoites are capable of 
invading erythrocytes and initiate the blood stage of the infection (fig 1.4).  
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1.3.2 The erythrocytic stage 
Following merosome disintegration, individual P. falciparum merozoites invade erythrocytes via a 
very efficient mechanism that involves the erythrocyte surface molecules glycophorins A/B/C 
and sialic acid as receptors [53-56]. Erythrocyte binding ligands (EBLs) are a family of Plasmodium 
type I transmembrane proteins that interact with reticulocyte binding proteins [57]. The existence 
of five paralogues of each in P. falciparum reflects the redundant pathways utilised by the parasite 
and the versatility it possesses in invading both normocytes and reticulocytes [33, 57]. Generally, 
rodent malaria strains are able to invade both normocytes and reticulocytes whereas human 
strains exhibit preference for normocytes [58]. Merozoite surface protein 1 (MSP-1) is inserted 
into the merozoite plasma membrane via a GPI anchor and is processed into five fragments from 
release to entry [33, 59]. The merozoite re-orients its apical end to face the erythrocyte surface via 
apical membrane antigen 1 (AMA-1) [60] and upon penetration the parasitophorous vacuole 
forms [61]. Each merozoite undergoes asexual reproduction leading to schizogony. 16-32 
merozoites are released upon rupture of the erythrocytic schizont and the asexual cycle is re-
initiated. Differentiation into male and female gametocytes eventually occurs, which are 
subsequently ingested by the female Anopheles mosquito as it takes a blood meal. Gametocytes 
differentiate into gametes within the mosquito midgut that fuse forming a zygote. This zygote 
multiplies and transforms into ookinetes with motile function. These traverse the midgut and 
encyst between the basal lamina and the midgut epithelia [62]. Ookinetes differentiate into 
oocysts consisting of mid-gut sporozoites, which migrate to the salivary gland and the infected 
mosquito re-initiates the infection-replication cycle [13] (fig 1.4).  
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Figure 1.4 Life cycle of the malaria parasite (from Epidemiology of Infectious Diseases, Johns 
Hopkins Bloomberg School of Public Health, OpenCourseWare) 
 
1.4 Malaria Immunopathogenesis 
1.4.1 The pre-erythrocytic stage 
Some sporozoites, once injected into the skin, present antigen to CD11c+ dendritic cells in the 
proximal lymph node after draining into the lymphatic circulation, while others remain in the skin 
[32]. However, the precise interaction of sporozoites with specialized DCs in the skin, such as 
Langerhans cells, and the role of innate immune signalling mechanisms (such as MyD88/Toll-like 
receptor signalling) remain unelucidated [33]. 
 
The liver is capable of autonomously priming CD8+ T cell responses in the absence of infiltrating 
APCs [63]. KCs, LSECs, Hepatic DCs, stellate cells and hepatocytes themselves are able to 
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present antigen [64], although with limited effector outcome as the liver feature a unique 
tolerogenic environment [65, 66]. Although it is unknown if parasite molecules retrotranslocate 
from the PV into the host cell cytoplasm to present antigen via MHCI [67, 68], as per DCs 
infected with Toxoplasma [41], DCs are capable of processing P. berghei circumsporozoite protein 
(CSP) in vitro and inducing P. berghei CSP-specific CD8+ T cell clones that produce IFN-γ [69]. 
CSP is the major sporozoite surface protein shed by the sporozoite during its motile behaviour 
and has been extensively utilized to study antigen-specific cellular immune responses [33].  
 
Upon merosome budding, the infected hepatocyte disintegrates and releases remnant parasite 
material [52] which leads to the formation of small granulomas as macrophages and neutrophils 
perform phagocytosis [33]. Granulomas, bundles of accumulated cells consisting primarily of 
macrophages, associated with severe inflammation [70], also form upon premature rupture of 
exoerythrocytic forms (EEFs) and host cell necrosis [33]. This inflammatory response varies 
according to the host and the parasite strain. Merosomes avoid KC phagocytosis in the liver 
sinusoid by not expressing phosphatidyl serine on their cell membrane [50].  
 
Since the pre-erythrocytic stage is pathologically silent and somewhat a bottleneck in the parasite 
life cycle, it is an excellent target for vaccines and therapies because successful elimination of the 
parasite would lead to protection from malarial disease. Indeed, proteins expressed during this 
phase, such as the UIS gene family, when knocked out, confer sterile protection against re-
infection [49] (discussed in 1.5.2). The pre-erythrocytic phase is the only stage of the parasite life 
cycle that can be eliminated by the induction of sterilizing immunity.  
 
1.4.2 The erythrocytic stage 
The erythrocytic stage of infection marks the onset of pathology in the afflicted individual. In 
malaria-endemic countries, adults and older children develop non-sterilizing immunity against the 
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malaria erythrocytic stage [71, 72]. Parasites retain a reservoir in such semi-immune individuals, 
which contributes significantly to the spread of infection. In non-immune individuals, 
erythrocytic rupture and the release of soluble parasitic products induces macrophages to 
produce IL-1 and TNF-α [73] and paroxysms of malarial fever are concurrent with the rapid 
production of pro-inflammatory cytokines such as TNF-α and IFN-γ [33, 74]. Macrophages, 
activated by TNF-α, secrete NO which upregulates intracellular cell adhesion molecule-1 (ICAM-
1) in leukocytes and endothelial cells. Infected erythrocytes activate DCs through toll-like 
receptors, ancient components of the innate immune system: pattern-recognition receptors that 
recognise both extracellular and intracellular “molecular patterns” [75]. Indeed, DCs are activated 
through TLR 9 and MyD88 [33, 76] and malarial GPI toxin activates TLR2 [77] and haemozoin 
acts as a ligand for TLR9 [78].  
 
Infected erythrocytes cytoadhere to the vascular endothelium to avoid clearance by the spleen 
[74]. In doing so, they cause damage to organs and, via binding to ICAM-1 and other receptors, 
cause cerebral malaria, described in further detail below (1.6). This binding generates a large 
inflammatory cascade marked by an overriding Th1 response involving TNF-α and IFN-γ, which 
in turn upregulates ICAM-1 on the endothelium and CD36 on platelets, which are primarily 
bound by the parasitic ligand PfEMP-1 [74]. IFN-γ plays a key role in malaria 
immunopathogenesis. It is first produced by NK cells [79] and it is assumed this cell subset 
bridges the gap between the innate and adaptive response [33]. 
 
The pro-inflammatory response, primarily consisting of IFN-γ and TNF-α, is tempered by a 
responding increase in TGF-β and IL-10 [80] produced in part by activated regulatory T cells that 
suppresses the pro-inflammatory response [81]. CD4+CD25+FOXP3+ regulatory T cells achieve 
this by producing a rapid burst of TGF-β during blood-stage infection [82]. IL-10- and IFN-γ-
producing CD4+CD45RO+FOXP3- regulatory T cells have been associated with regulation of the 
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immune response during acute infection in uncomplicated malaria, rather than severe disease 
[83]. 
 
Naturally acquired non-sterile protection against malaria is predominantly maintained by 
antibody-mediated immune responses [71, 72, 84, 85]. Antibodies play a key role in enhancing 
monocyte/macrophage activity, inhibiting the sequestration of parasitized erythrocytes and 
inhibiting erythrocyte invasion. Children who have not yet developed protection to malaria 
typically exhibit non-cryophilic antibodies (such as IgM, IgG2 and IgG4) whereas older 
individuals who have acquired resistance to malaria show marked increases in parasite-specific 
cryophilic antibodies (IgG1 and IgG) [86-88]. The events that lead to antigen-specific B cell 
activation at the blood-stage are currently unelucidated [33]. Despite some studies indicating that 
merozoite surface protein 1 (MSP-1)-specific antibody responses feature a seropositivity half-life 
of decades [89], protective parasite-specific antibody responses are apparently short-lived since 
titres decline following acute infection [71, 72] and are re-acquired upon subsequent infection, 
indicating inadequate generation of memory responses. Although studies into specific B cells are 
limited, expansion of FCRL4-expressing B cells [90], CD38+IgD and CD10+CD19+ cells in acute 
malaria [91] have been reported in exposed individuals, albeit antigen specificity and memory 
establishment and maintenance were not analysed.  
 
1.5 Parasite Attenuation and its Protective Effects 
Attenuation of the Plasmodium liver stage by radiation, gene knockout and drug treatment has been 
previously shown to cause vaccine-like sterilizing protection to subsequent wild-type challenge, 
mediated predominantly by CD8+ T cells [92-98]. These studies in attenuated strains have 
informed the majority of data pertaining to adaptive immune responses to Plasmodium.   
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1.5.1 Radiation Attenuated Sporozoites (RAS) 
Multiple immunizations with gamma-irradiation attenuated sporozoites render both humans and 
rodents completely protected against subsequent challenge with wild type sporozoites [94, 95]. 
This protective immunity is mediated by numerous mechanisms, including αβ CD8+ T cells and 
sporozoite-specific antibodies [98, 99] with a central role for IFN-γ [98, 100, 101] and can be 
transferred to naïve mice via adoptive transfer of both polyclonal antibodies and T cells [100, 
102, 103]. Interestingly, protection can also be established in an entirely class II restricted 
manner, in β2-microglobulin deficient mice, implicating CD4+ T cells and IFN-γ in protection 
[104]. Specifically, peptide-MHC recognized by CD8+ T cells activates them to produce IFN-γ, 
which in turn provokes the secretion of IL-12, itself stimulating NK cells to produce more IFN-γ 
in a positive feedback loop [105]. This causes the activation of the NO pathway, which induces 
the killing of the infected hepatocyte [33, 106, 107]. 
 
1.5.2 Genetically Attenuated Parasites (GAP) 
Murine parasites lacking genes that are critical for liver stage development [93, 108, 109] are a 
fairly recent development. These transgenic parasites are viable at the sporozoite stage and are 
able to successfully invade the liver but arrest prior to liver stage maturity, generating complete 
protective immunity against wild type sporozoite challenge in a manner comparable to radiation 
attenuated sporozoites [93, 108-113] mediated by MHC class I-dependent IFN-γ producing 
CD8+ T cells [97, 110]. Similar transgenic parasites have been produced in P. falciparum, 
indicating a potential translational approach to human vaccinology [114, 115].  
 
1.5.3 Chemical Attenuation and Chemoprophylaxis (CPS)  
An alternative option is to inoculate mice with wild type sporozoites under prophylactic drug 
cover, using an anti-erythrocytic antimalarial compound. Several drugs have been tested in this 
approach, although most studies have utilized chloroquine. Chloroquine is an antimalarial that 
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kills parasites within erythrocytes, accumulating at high concentrations within the blood-stage 
digestive vacuole [116]. This form of immunization, termed chloroquine chemoprophylaxis 
(CPS), permits complete pre-erythrocytic development of the parasite prior to its destruction by 
the compound upon egress from the liver into the blood [96]. Infection and the acquisition of 
immunity are thereby the result of natural wild type infection, as opposed to the attenuated 
infection induced by genetically modified or radiation exposed parasites.  
 
Immunization of whole sporozoites under prophylactic drug cover in this manner with 
chloroquine or primaquine generates protection against subsequent wild type challenge in a 
manner comparable to radiation and genetically attenuated parasites in both rodents [92, 117] and 
humans [118]. Protection is specific to the mediated by both CD8+ and CD4+ T cells, NO and 
IFN-γ [92] and a recent study found long-term responses are mediated by CD8+ IFN-γ producing 
hepatic memory T cells [96]. This protection is specific to the liver stage, rather than the blood 
stage, in both humans [119] and rodents (Lewis et al unpublished). In the case of primaquine drug 
attenuation, the long-term persistence of the metabolically-active parasite within the liver was 
shown to be vital in ensuring long-term immune responses [117], although the requirement for 
persistance has been questioned [120]. CPS with antibiotics that inhibit apicoplast biogenesis 
similarly provoke sterile protection in a comparable manner, provoking liver stage specfic 
responses that depend on CD8+ T cells and IFN-γ [121]. 
 
In a phase 1-2b trial of a recombinant blood-stage malaria vaccine in which sulphadoxine-
pyrimethamine was administered to clear prior infections [122], it was found that drug 
administration correlated with reduced incidence of severe malaria, including cerebral malaria. 
The authors speculate that this may be due to the drug causing low-dose blood stage inocula 
resulting in an attenuated infection [122-125].  
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1.6 Human Cerebral Malaria  
In the late 19th century, parasites were discovered in the brains of patients infected with malaria 
[126]. Today, human cerebral malaria (HCM) affects approximately 1% of all P. falciparum 
infections causing up to 500,000 deaths per year and long-term cognitive and physical 
dysfunction in those who survive the condition [127-129].  
 
The early symptoms of HCM occur after 2-3 days of fever and include malaise, fits, vomiting, 
headache and diarrhoea. These are not pathognomonic of HCM, rendering early diagnosis 
uncommon and treatment is often delayed until the rapid progression to late symptoms occur, 
including haemiparesis, ataxia and coma. Late presentation of disease results in relatively low 
survival rates of 85% and 80% to first-line antimalarial drugs artemisinin and quinine, respectively 
[130]. Immunomodulatory therapies that abrograte or alter the immunopathogenesis of HCM are 
lacking, largely due to lack of understanding of the complicated series of events by which HCM 
occurs. 
 
The brain pathology that leads to HCM has been partially revealed by post-mortem histological 
analysis of cerebral tissues.  Histopathological analyses have lead to the description of “classical” 
HCM as the plugging of cerebral capillaries with parasitized erythrocytes and margination of 
monocytes and macrophages within cerebral vessels [131-133]. This coincides with both swelling 
and haemorrhaging within the corpus callosum and subcortical rim. Haemorrhages within the 
cerebella and cerebral cortices are also evident [131].  
 
However, the classical presentation of HCM is not always consistent amongst patients. The 
absence of a detailed comparative analysis of cerebral pathology has led to numerous clinical 
descriptions of atypical HCM, not necessarily featuring the classical triad of leukocyte infiltration, 
perivascular haemorrhage and parasite sequestration. The reasons for atypical presentation are 
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unknown, although may be due to environmental factors, host immune responses or genetic 
variation between Plasmodium strains and hosts [133]. Indeed, two further non-classical 
histopathological presentations of HCM are reported in African children alone: Firstly, parasite 
sequestration in the absence of other typical signs and secondly, an “HCM-like” syndrome 
clinically defined as HCM but with no evidence of parasite sequestration in the cerebral tissues 
[133-135]. Furthermore, numerous differences exist between paediatric and adult HCM and it is 
unknown, although generally suspected, that pathology is not consistent between non-immune 
adults and children [136]. 
 
This is supported by epidemiological data relating to severe malaria, including HCM. Adults in 
endemic areas acquire non-sterilizing immunity to malarial infection and severe malaria is a 
complication almost exclusively associated with infancy [137]. However, HCM does not occur in 
children upon first infection, but after exposure to at least one prior infection [133, 137]. This is 
in contrast to non-immune adults who travel to endemic regions and develop HCM upon first 
infection with a higher mortality rate than non-immune children. Artavanis-Tsakonas and 
colleagues suggest that this may be because first infection of an infant living in an endemic area 
induces only low levels of both IFN-γ and TNF-α by the innate immune response since T cells 
are not yet primed to parasite-specific antigen. The authors suggest that clinical symptoms are 
minimal due to maternal antibody, cytokine-mediated killing or physiological barriers, such as 
dietry deficiencies. However, upon subsequent infection, the authors hypothesize that primed T 
cells produce increased IFN-γ leading to HCM and systemic shock. Over time, if the child 
survives repeated infections, the immune response becomes more efficient at reducing 
parasitemia an the level of antigenic stimulation is in turn reduced, thereby decreasing the 
inflammatory response and incidence of HCM. This is correlated with a switch in lymphocyte 
subsets from Th1 to Treg, producing IL-10 and TGF-β rather than IFN-γ In contrast, the 
authors suggest that non-immune adults develop overriding inflammatory responses upon first 
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infection due to cross-reactivite priming of T cells. Non-immune children, however, have fewer 
cross-reactively primed lymphocytes due to exposure to fewer cross-reacting pathogens, therefore 
experience less incidence of HCM [137] (fig 1.5). 
 
1.7 Experimental Cerebral Malaria  
Since HCM studies are largely restricted due to late presentation of symptoms and obvious 
ethical considerations, little work has been done to uncover the immunological processes in 
HCM immunopathogenesis beyond descriptive studies. In vivo imaging techniques including 
magnetic resonance spectroscopy, computational topography and magnetic resonance imaging 
are reversing this trend, but are hampered by ethical and financial constraints [133, 138-142]. 
Hence experimental models have been relied upon to uncover the pre-clinical features and 
immunopathogenesis of disease.  
 
Some studies have been conducted in squirrel [143] and rhesus [144, 145] monkeys but such 
studies are restricted due to ethical and financial considerations. Infection of inbred mouse strains 
with lethal P. yoelii [146] and P. berghei [147, 148] has been shown to mimic human cerebral 
symptoms but by far the infection of C57BL/6 mice with Plasmodium berghei ANKA (PbANKA) is 
the best animal model for the disease [133] termed Experimental Cerebral Malaria (ECM). 
 
The onset and progression of ECM occurs rapidly between days 5 and 10 post-infection and 
includes fitting, ataxia, respiratory distress and coma leading to death within 5 hours [149]. 
Symptoms can be scored against the Rapid Murine Coma and Behavior Scale (RMCBS) [150] 
(Appendix 1) to aid diagnosis and quantitative description of disease pathology. Scoring typically 
progress from < 5 to 20 within one day. 
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Figure 1.5 Hypothetical model for the clinical immunity to P. fa l c iparum dependent upon age at 
first exposure (Artavanis-Tsakonas, 2003)[137]. 
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ECM causes blood-brain barrier damage and vascular leakage associated with the olfactory bulb, 
cortex and cerebellum [141, 151], destruction of neuronal populations in the striatum and cortex 
[152], inflammation in the perivascular region [153] and accumulation of parasitized erythrocytes 
[147, 154] and platelets [155, 156] within the brain microvasculature, the latter of which cause 
damage to endothelial cells [133, 157]. In addition to the pathological symptoms, these factors 
cause cognitive dysfunction and impaired visual memory [158]. A recent study employing 
intravital microscopy indicated that ECM is associated with platelet marginalization, CD14 
expression, fibrin deposition and vascular leakage in the postcapillary venules, rather than the 
capillaries or arterioles. Microhaemorrhaging was rarely reported and it was concluded that ECM 
pathology is caused by the opening of the transcellular-vesicular fluid transport and paracellular-
junctional pathways at the blood-brain barrier (BBB) [159].  
 
Susceptibility of C57BL/6 mice to ECM is dependent upon environmental exposure and age; 
animals older than 16 weeks are generally resistant [154]. Genetic factors are also involved in 
ECM susceptibility, with (as-yet-unknown) genes encoded within chromosomes 1, 9, 11, 17 and 
18 identified as responsible via crossing of resistant and susceptible mouse strains [133, 160-163]. 
Furthermore, distinct gene expression profiles involved in apoptosis, immune-activation, 
neurotoxicity and neuroprotection have been identified in the brain [133, 164-166].  
 
Controversy exists about the accuracy and relevance of ECM as a model to study HCM [167-169]. 
The majority of concerns have focused on the role of parasite sequestration, an apparently 
integral component of HCM immunopathogenesis, and its relevance in the ECM model [170, 
171] and the translational relevance of interventions in the murine model to human therapy [168]. 
Since mouse brains are often perfused before histopathological investigation, a practice that is 
rarely employed in the preparation of materials from human subjects, the extent of parasite 
sequestration in ECM may be underestimated [133]. Indeed, a recent study demonstrated that 
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treatment with an antimalarial 15-20h prior to the onset of ECM symptoms delays pathology 
until parasitemia returns to the same level at pre-treatment. This does not alter the number of 
CD8+ T cells in the brain, and the authors conclude that parasite sequestration is an integral 
component of ECM immunopathogenesis [172]. Nonetheless, blocked cerebral vessels in ECM-
symptomatic animals contain a mixture of leukocytes and parasitized erythrocytes [154, 173]. 
Sequestration alone is likely not adequate for ECM pathology. Sequestration remains a largely 
uninvestigated aspect of ECM pathology, although brain-localized parasite biomass has been 
correlated with ECM [174, 175], albeit not by binding to CD36 [133, 171].  
 
1.8 Immunopathogenesis of Experimental Cerebral Malaria 
The immunopathogenesis of cerebral pathology in both HCM and ECM is a complicated series 
of inter-related events involving multiple organs, parasite and host immune factors over a period 
of some 5-10 days. The precise events that lead to BBB breakdown and cerebral pathology are 
not entirely elucidated although the literature has enabled postulation of a hypothetical scheme of 
events that results in the definitive endpoint: alteration of the BBB and the onset of ECM 
symptoms [176-181]. In toto the literature indicates that ECM immunopathogenesis involves a 
multifaceted Th1 host response with an essential requirement for IFN-γ [182] and lymphotoxin-β 
[153, 183] and that the balance between pro-inflammatory and regulatory T cell responses [184-
186], rather than Th2 responses [187] ultimately determines susceptibility [133]. Despite it being 
partly suppositional, the literature yields a comprehensive dataset that allows a corresponding 
series of events to be presented as a hypothetical schema for ECM immunopathogenesis (fig 1.5). 
As per the literature, schematic descriptions of the events that lead to both HCM and ECM 
typically commence at the rupture of infected erythrocytes, rather than the pre-erythrocytic stage 
(the steps involved in ECM immunopathogenesis described below are mostly adapted from 
Renia et al 2006 and de Souza et al 2010) [181] [133]: 
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STEP ONE:  Parasitized erythrocytes adhere to endothelial cells in the brain and other 
peripheral tissues, inducing chemokine secretion and activation of the endothelium. At 
the same time, parasitized erythrocytes rupture and induce monocyte, neutrophil and DC 
activation. A state of systemic inflammation is established. 
Malaria infection commonly features the sequestration of mature parasites within peripheral 
tissues to avoid immune clearance in the spleen via binding to the vascular endothelium [188]. 
Pro-inflammatory cytokine levels, mostly IFN-γ, TNF-α and lymphotoxin, are significantly 
increased [182, 189], activate the endothelium and upregulate adhesion receptor expression. 
Parasites adhere to liver, lung and brain tissue and induce chemokine secretion. Chemokine 
production and expression of chemokine-receptors on leukocytes is upregulated [190-192]. 
Indeed, PbANKA infection causes upregulation of CCL2 (MCP-1), CXCL10 (glP-10) and CCL5 
(RANTES) expression, the latter of which is specifically associated with ECM [193].  
 
A proportion of infected erythrocytes that do not sequester undergo clearance in the spleen 
[194], the secondary lymphoid organ that filters the blood and filters blood-borne organisms 
from the blood circulation [195]. Within the spleen, antigen uptake and processing is performed 
by CD11chighCD8+ DCs, which are responsible for ECM immunopathogenesis [196]. Parasites 
associate with CD11chiCD8+ DCs, which capture dying cells and exogenously process antigen for 
cross-presentation via MHCI [197]. Activation of the innate branch of the cellular immune 
system is a key feature of the early immune response in ECM, monocytes and macrophages in 
particular, and is believed to be an essential component of ECM immunopathogenesis at this 
early time point [198-200]. 
 
STEP TWO: Neutrophils and monocytes migrate to the brain via chemotaxis  
During fulminant infection, brain-sequestered leukocytes express CCR2 and CCR5. While the 
former has been shown to be non-essential [201], the latter is required for full ECM 
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development, with CCR5-deficient animals exhibiting reduced leukocyte brain infiltration [202, 
203]. Neutrophils and monocytes express these receptors and, via chemotaxis, migrate to the 
brain where they remain intravascular, a classic and unique indicator of cerebral pathology [132, 
204]. The blood-brain-barrier is made up largely of endothelial cells [205]. Neutrophils and 
monocytes bind to the brain endothelium via ICAM-1 and LFA-1, which is upregulated on 
activated brain endothelial cells [178] in addition to P selectin and VCAM-1 [190, 192]  and, in 
the case of ICAM-1, this upregulation is essential for the development of ECM [206]. This early 
migration of innate leukocytes to the cerebral tissues causes initial damage to the BBB and 
stimulates more chemokine and cytokine production [181].  
 
STEP THREE: Naïve T cells are primed in an antigen-specific manner by CD11c+ DCs 
and activated T cells migrate to the brain in response to chemokines 
Several days post-infection, naïve T cells are fully primed by CD11chighCD8+ DCs [196] and these 
cells migrate to the brain in a full assault of the blood-brain-barrier. This phase represents the 
central component of ECM immunopathogenesis and is responsible for severe symptoms and 
mortality. DCs present antigen to CD4+ and CD8+ T cells and CD4+ T cells assist CD8+ T cell 
activation and proliferation, possibly via the CD40/CD40L system [207]. 
Following cross-presentation by DCs, IFN-γ derived from NK cells upregulates chemokine-
receptor CXCR3 on CD8+ T cells [208] and they migrate to the brain in an antigen-specific 
manner via chemotaxis [209-211] to IFN-γ induced chemokines as described in step two.  
 
STEP FOUR: CD8+ T cells accumulate within the cerebral vessels, recognise and kill 
endothelial cells presenting parasite antigen by MHCI on their surface  
In addition to CD8+ T cell chemotaxis, CXCR3 upregulation by IFN-γ derived from NK cells 
mediates CD8+ T cell accumulation within the cerebral tissues [208] and IFN-γ signalling 
mediates their sequestration within the brain [212]. Antigen-specificity is mostly unknown, 
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although 50% of brain-sequestered CD8+ T cells bear the same Vβ 8 segment in their T-cell 
receptor as a dominant and expanding subset of CD8+ T cells in the periphery, indicative of a 
dominant parasite epitope [213].  
 
Activated endothelial cells efficiently present antigen [214] and it has been suggested that Th1-
cytokine-activated endothelial cells resident in both brain and other tissues phagocytose parasite-
derived material from sequestered parasites and present antigen to CD8+ T cells [181]. PbANKA 
infection induces the upregulation of both MHCI and II on cerebral endothelial cells [215] and 
studies in MHC-impaired transgenic mice suggest a crucial role for MHC presentation in ECM 
immunopathogeneis [213].  
 
Studies into the cytotoxic mechanism of CD8+ T cells sequestered within the brain 
microvasculature have yielded assorted results. The perforin pathway is one potential candidate 
for targeted killing since perforin-deficient mice do not develop ECM [203, 216]. Fas-deficient 
mice did not develop ECM in one study [216] but did in others [203, 217] and the TNF factor 
pathway can be excluded on the basis that TNF-α deficient animals succumb to ECM [153]. 
 
STEP FIVE: The blood-brain barrier ruptures and haemorrhages  
The migration of CD8+ T cells to the cerebral vessels and their cytotoxic activity on the 
endothelium is directly responsible for the damage to the blood-brain-barrier that is the hallmark 
of ECM pathology. CD8+ T cell depletion at both early and late infection prevents ECM 
pathology [217-219]. Ultrastructural changes to the blood-brain-barrier occur and severe 
perturbation causes perivascular oedema and haemmorhaging [178, 220] and, as a result, ECM 
symptoms and death occur within hours [176-180]. 
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Figure 1.6 The immunopathogenesis of cerebral malaria (de Souza et al, 2010) [133] Parasitized 
erythrocytes rupture and the resultant Th1 response and released molecules cause the activation of 
endothelial cells and parasite-specific receptors. Phagocytosis of parasite moieties causes the priming of 
lymphocytes within the spleen, in turn promoting systemic inflammation and further activating endothelial 
cells, microglia, perivascular macrophages and astrocytes within the brain. Endothelial receptors and 
bound platelets bind parasitized erythrocytes. Lymphocytes and myeloid cells chemotax to the brain 
guided by chemokines produced by glial cells and the activated endothelium. Leukocytes and parasitized 
erythrocytes bound to the endothelium interefere with the circulation and produce cytotoxic molecules. 
This damages the blood-brain-barrier and causes haemorrhages and oedema. (Legend adapted from de 
Souza et al [133]). 
 
1.9 T cells in ECM Immunopathogeneis and Immunopathology 
The crucial role of T cells in ECM immunopathology cannot be overstated (fig 1.6 and 1.7). 
ECM mice feature a thirty-fold increase in brain-sequestered CD8+ CD3+ T cells compared to 
naïve animals and fifteen-fold compared to infected but non-cerebral animals [202]. CD8+ T cell-
depleted mice do not succumb to ECM [217] and splenic CD8+ T cells adoptively transferred 
from ECM-suffering mice to RAG-2-deficient donors, normally resistant to ECM [203, 217, 218, 
221-223], migrate to the brain and cause ECM pathology [181, 203]. Studies into the specific 
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surface marker expression of sequestered CD8+ T cells in ECM yield contrasting data: CD44+ 
CD62L- LFA-1+ ICAM-1+ CD8+ T cells were isolated from homogenized brain tissue purified by 
percoll gradient [203, 213] whereas CD44low CD62Llow LFA-1low ICAM-1low CD8+ T cells were 
isolated from collagenase-treated brain tissue isolated from intracardially-perfused animals [181]. 
Renia et al speculate that these apparently contradictory data may represent two distinct 
populations of CD8+ T cells: a recently-arrived activated subtype and an earlier subset that have 
downregulated their expression markers following interaction with monocytes and platelets or 
endothelial cells [181].  
 
The precise role of CD4+ T cells has not been elucidated, and though they undoubtedly represent 
a central component in ECM immunopathogenesis [217, 218, 223], their role is either restricted 
to the innate or induction phase of ECM depending upon the PbANKA clone and mouse strain 
utilised [217, 218, 224, 225]. There is a 9-fold increase in their sequestration in the brains of ECM 
animals as compared to non-cerebral [202] but their precise role in the induction versus effector 
mechanisms of ECM pathology is not clear.  In C57BL/6 mice infected with PbANKA clone 
BdS, late (days 5-6) CD4+ T cell depletion had no effect on ECM outcome, but early (days 0-3) 
depletion did have an effect, suggesting that in the classic ECM model, CD4+ T cells play an 
essential role in the induction of ECM and activation of CD8+ T cells [217]. In one study, in 
which CD4+ T cells were purified from brain tissue homogenates, they were of the CD44+ 
CD62L- effector memory subset [203].  
 
In addition to αβ T cells, there is an increase in γδ T cells sequestered in the brain 
microvasculature in ECM mice [217]. Although they do not have an effector function in ECM 
immunopathogenesis [225], they may play a role in ECM induction, since depletion of γδ T cells 
at very early blood-stage infection has been shown to prevent ECM [181, 223, 225]. 
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1.10 Disrupting the immunopathogenesis of Experimental Cerebral Malaria 
Numerous studies have interrupted the finely tuned balance of interrelated events that lead to 
cerebral pathology in mice. The overall host inflammatory response is of paramount importance 
to cerebral immunopathogenesis and it is unsurprising that the C57BL/6 mouse strain, which has 
a strong Th1 bias [226], produces the model reaction of overriding pro-inflammatory responses 
that cause pathology. This is comparable to the human situation, in which polymorphisms in 
genes associated with the innate immune response, such as the IL-10 promoter, cause IL-10  
 
 
Figure 1.7 The role of T cells in Experimental Cerebral Malaria (Renia et al, 2006) [181] At blood 
stage infection, increasing blood stage parasitemia and rupture of infected erythrocytes is associated with 
phagocytosis of parasite moieties by splenic CD8+CD11c+ dendritic cells, which exogenously process 
antigen via MHCI, prime and activate lymphocytes and cause systemic inflammation, associated with pro-
inflammatory cytokines such as IFN-γ. Systemic inflammation and parasitized erythrocytes activate 
neutrophils and monocytes, which migrate to the brain from day 4 by chemotaxis through receptors 
CCR2 and CCR5, amongst others, and bind to the endothelium through adhesion molecules LFA-1, 
ICAM-1 and others. Systemic inflammation increases endothelial activation in the brain, increased 
binding of infected erythrocytes to endothelial receptors and increased migration of lymphocytes from 
the spleen to the brain microvasculature in response to chemokines. Primed lymphocytes migrate to the 
brain in a similar manner. Leukocyte and parasite sequestration damages the blood-brain barrier and leads 
to cerebral pathology, possibly through antigen-specific T cell cytotoxicity, via MHCI restricted 
presentation of parasite-derived antigen on endothelial cells; haemorrhaging, coma and death results. 
(Legend adapted from Renia et al [181]). 
 
promoter haplotypes that confer a high IL-10 : IL-12 ratio. Individuals with these haplotypes 
feature decreased IFN-γ production, correlated with increased incidence of malarial anaemia 
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[227] and presumably reduced incidence of HCM. The inflammatory response that leads to 
ECM in susceptible mice can be downregulated by various means to prevent the development of 
cerebral pathology. For example, neutralization of TNF-α was historically thought to prevent 
the development of ECM [200, 228-230] until later studies found that related cytokine 
lymphotoxin-α is responsible [153] via signalling through LT-beta and TNF receptor 2 [181, 
183]. Similarly, neutralization of IFN-γ [182] and depletion of macrophages [229] has been 
shown to prevent ECM development. Additionally, neutralization of IL-10 causes ECM-like 
cerebral symptoms and brain pathology in C57BL/6 mice infected with non-ECM inducing 
parasite strains [231] (A Joschko MSc Thesis 2012). Conversely, studies in Th2-biased mouse 
strains have found that ECM symptoms can be provoked in non-ECM-susceptible mice by 
modulating the immune system to produce an inflammatory response. This has been 
demonstrated by administration of endotoxin (concomitant with increased TNF-α production) 
[232], inhibition of CTLA-4 signalling [233], administration of CpG [234], neutralisation of 
haeme oxygenase 1 [235] and neutralisation of the anti-inflammatory cytokine IL-10 [184] in 
non-susceptible mouse strains. Despite its crucial importance, the exact role of IL-10 in the 
suppression of ECM immunopathogenesis has not been fully elucidated, since IL-10 is produced 
in abundance in both the plasma [174] and spleen [236] of ECM-symptomatic mice, possibly as 
the result of a cytokine storm.  
 
Co-infection of ECM-susceptible mice with PbANKA and other parasite strains or infections is 
associated with protection from ECM. This may be due to modulation of key factors in the 
innate immune response and/or the activation of dendritic cells and it has been suggested that 
non-ECM parasite strains may activate a different subset of dendritic cells that leads to a 
reduction and/or failure in the priming and expansion of lymphocytes [237]. Indeed, co-
infection of PbANKA with murine AIDS [238], Filaria [239], nonlethal PbXAT [240] and Py 
17XNL [241] protects against ECM by downregulation of the Th1 response. In the former 
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three, protection is mediated via the upregulation of IL-10, with protection abolished in the 
absence of this cytokine [238-240] but in the latter case protection is independent of IL-10, 
CD4+CTLA-4+ and CD4+CD25+ cells [238, 240, 241]. In contrast, ECM induced by normal 
PbANKA infection can be ablated independently of IL-10 by the expansion of regulatory T cells, 
via IL-2/anti-IL2 complexes. This protection is dependent on CTLA-4 and features a marked 
reduction in the recruitment of CD8+ and CD4+ lymphocytes to the cerebral microvasculature 
[242]. Interestingly, the oral administration of activated charcoal, which is highly effective at 
adsorbing cytokines such as IL-6, TNF-α and IL-1 [243] has been demonstrated to protect 
against both ECM and HCM [244] and is being expanded into clinical trials. Few studies have 
examined the effect of antimalarial treatment on malaria immunopathogenesis. It has been 
demonstrated that treatment of infected mice with an antimalarial prior to the onset of ECM 
symtoms – the usual endpoint of infection – attenuates infection by decreasing parasitemia and 
causing a delay in the onset of cerebral pathology. [172]. Another study of antimalarials indicated 
that attenuation of early blood-stage infection may show similar effects. [245].  
 
Very few studies have examined early cellular immune responses associated with parasite 
attenuation in terms of its role in protection from cerebral pathology. This is in contrast to 
studies of vaccine-like sterilizing immunity, such as those produced by GAP and RAS, which 
have been extensively studied at the pre-erythrocytic stage. Co-infection of ECM-susceptible 
mice with PbANKA and PbK173, which results in protection from ECM, was found to be 
associated with increased IFN-γ at 24 hours post-infection and an increase in transcriptional 
abundance of IFN-γ, IL-10 and IL-12 [236]. Interestingly, an early Th1 peak was also apparent in 
PbK173 infection alone and was credited as the protective agent against cerebral pathology, by 
altering downstream ECM immunopathogenesis. The source of IFN-γ was identified as β2-
microglobulin specific, a component of MHC-I [246], and not NK, γδ T cell or NKT cell-
specific. From these data the authors hypothesized that the source of IFN-γ is CD8+ T cells, 
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which, despite being classically defined as a component of the adaptive immune response, are 
able to rapidly produce the cytokine non-clonally via bystander activation under numerous 
conditions, such as LPS [247] and bacterial [248-250] challenge. In another study, the vaccination 
of susceptible animals with irradiated blood stages was found to prevent the development of 
ECM in susceptible animals upon challenge with non-irradiated parasites [251]. Vaccinated 
animals produced splenic IFN-γ when challenged with parasite antigen and, while the source of 
the cytokine is not addressed, the authors speculate that early IFN-γ produced by splenic 
lymphocytes is responsible for protection. 
 
Very few studies have examined the pre-erythrocytic stage or the interaction between liver and 
blood that occurs in early infection on the immunopathogenesis of ECM. Some initial work has 
indicated a potential role for the liver stage in modulation of disease severity. A recent study 
reported that a transgenic parasite line lacking a Plasmodium-specific apicoplast protein resulted in 
attenuated merozoite formation and impaired liver-stage development. This is turn correlated 
with a reduced incidence of cerebral pathology [252].  
 
1.11 Hypothesis 
ECM is caused by a complicated series of interrelated events that involves both host and 
parasite, systemic and organ-specific pathology and immune responses (fig 1.8). Hypothetical 
descriptions of ECM immunopathogenesis have classically started at the onset of blood stage 
infection, which is coincident with systemic pathology, the induction of innate immunity and the 
priming of the adaptive immune response. The pre-erythrocytic and very early stages of the 
disease have been largely overlooked in the literature, despite some evidence to suggest that early 
immune responses, specifically inflammatory responses, are capable of altering downstream 
immunopathogenesis in a manner that involves CD8+ T cells and IFN-γ [236, 251]. As described 
above, the attenuation of Plasmodium at the pre-erythrocytic stage via various means, such as 
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GAP, RAS and CPS can provoke the host immune response to generate protective immunity 
against subsequent infection.  
 
1. I propose that it is possible to attenuate Plasmodium liver stage development as a means of 
manipulating the host immune response to alter the clinical outcome of ECM via sub-
therapeutic chemoprophylaxis in a manner similar to GAP, RAS and CPS. Chemoprophylaxis 
must necessarily be administered at a sub-therapeutic dosage to permit the development of the 
parasite successfully through the liver stage.  
 
2. Since all forms of pre-erythrocytic parasite attenuation (RAS, GAP and CPS) have been 
demonstrated to manipulate the host immune response via induction of CD8+ T cells and IFN-γ, 
I hypothesize that sub-therapeutic chemoprophylaxis of the parasite at the pre-erythrocytic stage 
will induce CD8+ T cells earlier and in greater abundance than would occur in natural infection. I 
further hypothesize that induced CD8+ T cells will modulate the outcome and severity of 
cerebral pathology in C57BL/6 mice infected with PbANKA sporozoites by the induction of a 
cell-mediated Th1 response that occurs earlier than in natural infection. This response will 
deregulate downstream systemic Th1 responses and reduce CD8+ T cell priming that normally 
occurs much later in infection. 
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Figure 1.8 The pre-erythrocytic / erythrocytic immunopathogenesis of Experimental Cerebral 
Malaria . Following sporozoite invasion, parasites undergo pre-erythrocytic development in the liver prior 
to the onset of blood stage infection. No significant protective pro-inflammatory response occurs at either 
liver or spleen at the pre-erythrocytic stage. At blood stage infection, increasing blood stage parasitemia 
and rupture of infected erythrocytes is associated with phagocytosis of parasite moieties by splenic 
CD8+CD11c+ dendritic cells, which exogenously process antigen via MHCI, prime and activate 
lymphocytes and cause systemic inflammation, associated with pro-inflammatory cytokines such as IFN-γ. 
Systemic inflammation increases endothelial activation in the brain, increased binding of infected 
erythrocytes to endothelial receptors and increased migration of lymphocytes from the spleen to the brain 
microvasculature in response to chemokines. This leukocyte and parasite sequestration damages the 
blood-brain barrier and leads to cerebral pathology, possibly through antigen-specific T cell cytotoxicity, 
via MHCI restricted presentation of parasite-derived antigen on endothelial cells; haemorrhaging, coma 
and death result.
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Chapter 2 
Materials and Methods 
2.1.1  Materials 
Computer software: 
7500 Software v2.0.5     Applied Biosystems, USA 
CellQuestPro      BD Biosciences, Germany 
Endnote X4  Thomson Reuters, USA 
FCAPArray software      BD Biosciences, Germany 
Magellan V 5.0 software   Tecan, Austria 
Microsoft Excel for Mac 2008    Microsoft Corporation, USA 
Microsoft Powerpoint for Mac 2008   Microsoft Corporation, USA 
Microsoft Word for Mac 2008   Microsoft Corporation, USA 
Laboratory equipment: 
ABI 7500       Applied Biosystems, USA 
BD FACSCanto     BD Biosciences, Germany 
BD FACSCalibur     BD Biosciences, Germany 
Centrifuge 5415 R     Eppendorf, Germany 
Cryotome      Leica Microsystems, Austria 
Freezer -20°C      Liebherr, Germany 
Freezer -80°C HeraFreeze Top   Thermo Scientific, Germany 
Fridges  Liebherr, Germany 
Hemocytometer, Neubauer    Labotec, Labor-Technik, Germany 
Hera Cell Incubator     Heraeus Instruments, Germany 
Ice machine ZIEGRA     Isernhagen, Germany 
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Light optical microscope, Axiostar plus   Zeiss, Germany 
Light optical microscope, Axioskop   Zeiss, Germany 
Light optical microscope, Axiovert 25   Zeiss, Germany 
Liquid nitrogen tank      CBS, USA 
Magnetic stirrer   Heidolph MR3001 NeoLab, Germany 
Megafuge 1.0R      Heraeus Instruments, Germany 
Microwave oven     MDA, Germany 
Mosquito cages      BioQuip Products Inc, USA 
NanoDrop ND-1000     Thermo Fischer Scientific, USA 
pH-meter       Inolab, Germany 
Photometer Eppendorf     Eppendorf, Germany 
Pipetman Gilson  (P2, P20, P200, P1000)  Abimed, Germany 
Scales       Sartorius, Germany 
Sterile work bench  Gelaire, BSB4A Flow Laboratories, 
Germany 
SUNRISE Absorbance Reader   Tecan, Austria 
Superfrost/Plus slides  Microm International, Germany 
Vacuum membrane pump     KNF Neuberger Laboport,Germany 
Vortex Genie 2   Scientific Industries Roth,Germany 
Water Bath      GFL, Germany 
 
2.1.2  Disposables 
96-well cell culture plate     Sarstedt, Germany 
Aluminum foil      Roth, Germany 
Cell strainer      BD Bioscience, (70µm Nylon) 
Centrifuge tubes (15 ml, 50 ml)    Sarstedt, Germany    
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Falcon tubes (15ml, 50ml)  Sarstedt, Germany 
Gloves, Peha soft satin  Hartman, Germany 
Immersion oil       Waldeck, Germany 
Microfuge tubes (0.5 ml, 1.5 ml, 2.0 ml)   Sarstedt, Germany 
Microscope cover slips     Marienfeld, Germany 
Needles  BD DiscarditII (0.4mm x 19 mm;  
0.6 mm x 30 mm; 0.9 mm x 40 mm) Becton 
Dickinson, Germany 
Nunc Lab-Tek II Chamber Slide System  Thermo Scientific, Germany 
Object slides       Marienfeld, Germany 
Parafilm       Pechiney Plastic Packaging, USA 
Petri dishes  
(145 x 20 mm; 94 x 16 mm)     Sarstedt, Germany 
Pipettes (1 ml, 5 ml, 10 ml, 25 ml),    Sarstedt, Germany  
Pipette tips       Sarstedt, Germany 
Syringe  BD Discardit II (U-100 Insulin, 1 ml, 5 ml,  
20 ml) Becton Dickinson, Germany 
Sterile filter millipore bottle  Sarstedt, Germany 
Thermo Fast 96 PCR detection plate  Thermo Scientific, Gemany 
UV-micro cuvettes      Micro Brand, Germany 
 
2.1.3  Chemicals 
Bovine Serum Albumin (BSA)    Roth, Germany 
Brefeldin A      Sigma, Germany 
Collagenase (Clostridium histolytica)   Sigma, Germany 
Complete protease inhibitors    Roche, Germany 
Materials and Methods   
 34  
Cremaphor RH 40     BASF, Germany 
DMSO       Sigma Aldrich, Germany 
Easycoll Density 1.124 g/ml    Biochrom AG 
Eosin       Thermo Fisher Scientific, US   
Ethylenediaminetetraacetic acid (EDTA)   AppliChem, Germany 
Evans blue      Sigma, Germany 
Fetal calf serum (FCS)     Gibco Invitrogen, Germany 
Formamide      Merck, Germany 
Giemsa (0,4%, w/v)  Roth, Germany (for rodent parasitemia 
analysis) and Thermo Fischer Scientific, 
USA (for histological anaylsis) 
Haemotoxylin      Thermo Fisher Scientific, US   
Hanks Balanced Salt Solution (HBSS)   Gibco Invitrogen, Germany 
Heparin      Rathiopharm, Germany 
KHCO3      AppliChem, Germany 
Ionomycin  Sigma-Aldrich, Germany 
Formaldehyde (4%)      AppliChem, Germany 
NH4Cl       AppliChem, Germany 
Non-essential amino acids    Gibco Invitrogen, , Germany 
Methanol      Applichem, Germany 
1 x PBS      Gibco Invitrogen, Germany 
Penicillin (10000 U/ml)    GibcoBRL, Germany 
Streptomycin (10000µg/ml)    GibcoBRL, Germany 
Phosphate Buffered Saline (PBS)-pellets   Gibco Invitrogen, Germany 
PMA  Sigma-Aldrich, Germany 
RPMI 1640 (+25 mM HEPES, 
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+ L Glutamine) w/ and w/o phenol red  Gibco, Germany 
Saponin        Sigma, Germany 
Sodium pyruvate     Gibco Invitrogen, Germany 
Trypan blue Sigma-Aldrich, Germany 
 
2.1.4 Buffers 
10 x PBS (pH 7)  50 PBS-pellets dissolved in 1l ddH20 
 
CBA Buffer 100 ml 1 x PBS 
2 tablets of complete protease inhibitor 
cocktail (Roche, Mannheim), 0.05 % Tween 
20 
 
MACS Buffer 1 x PBS 
0.5 % BSA  
2 mM EDTA 
 
Red cell lysis Buffer     1 liter ddH2O 
8.26 g NH4Cl 
1 g KHCO3 
0.037 g EDTA 
 
Saponin Buffer 1 x PBS 
0.1% BSA 
0.3% Saponin 
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2.1.5   Media 
Growth Media RPMI (Life Technologies, Germany) 
10 % FCS 
5 ml Non-essential amino acids 
5 ml Sodium pyruvate 
5 ml 1 M HEPES, pH 7,5 
5 ml penicillin / streptomycin 
10 µl heparin  
Hepatocyte culture media  1 x Dulbecco’s Modified Eagle Medium 
  10% FCS 
  1% penicillin / streptomycin 
2.1.6   Parasite media 
Freezing solution     Glycerin : Alsever´s solution (1:9) 
Sporozoite-isolation medium (P. berghei)   3% BSA in RPMI 1640 
 
2.1.7  Antibodies 
 
Antibody Concentration Clone Working 
Dilution 
Manufacturer 
APC Rat α-
Mouse CD25 
0.2 mg/ml PC61.5 1:150 
 [0.6 µg/ml] 
BD Bioscience 
APC Rat α-
Mouse CD3 
0.2 mg/ml 17A2 1:150 
 [0.6 µg/ml] 
eBioscience 
APC Rat α-
Mouse CD44 
0.2 mg/ml IM7 1:150 
 [0.6 µg/ml] 
eBioscience 
APC Rat α-
Mouse 
TNFα 
0.2 mg/ml MP6-XT22 1:150 
 [0.6 µg/ml] 
eBioscience 
FITC Rat α-
Mouse CD4 
0.5 mg/ml GK1.5 1:150 
 [1.5 µg/ml] 
eBioscience 
FITC Rat α-
Mouse IFNγ 
0.5 mg/ml XMG1,2 1:150 
 [1.5 µg/ml] 
eBioscience 
Table 1: Fluorescent antibodies 
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PE Rat α-
Mouse CD4 
0.2 mg/ml L3T4 1:150  
[0.6 µg/ml] 
BD Bioscience 
PE Rat α-
Mouse 
CD62L 
0.2 mg/ml MEL-14 1:150  
[0.6 µg/ml] 
BD Bioscience 
PE Rat α-
Mouse IL-2 
0.2 mg/ml JES6-5H4 1:150  
[0.6 µg/ml] 
BD Bioscience 
PE-Cy7 Rat 
α-Mouse 
CD69 
0.2 mg/ml H1.2F3 1:150  
[0.6 µg/ml] 
BD Bioscience 
PerCP Rat α-
Mouse CD4 
0.2 mg/ml RM4-5 1:150  
[0.6 µg/ml] 
BD Bioscience 
PerCP Rat α-
Mouse CD8a 
0.2 mg/ml 53-6.7 1:150  
[0.6 µg/ml] 
BD Bioscience 
Rat α-Mouse 
CD16/CD32 
0.5 mg/ml 2.4G2 1:200  
[1.3 µg/ml] 
BD Bioscience 
 
Table 2: Immunofluorescence antibodies  
 
Antibody Concentration Manufacturer / Source 
α-Pb HSP70 (Mouse) Undiluted Hybridoma supernatant [253] 
ALEXA Fluor 488 
(Goat α-Mouse) 
1:1000 Invitrogen, Germany 
Hoechst 1:1000 Invitrogen, Germany 
 
Table 3: Depleting antibodies 
 
 
 
 
Antibody Concentration Clone Manufacturer 
LEAF Purified  α-mouse CD8 250 µg/ml 53-6.7 Biolegend, 
LEAF Purified α-mouse CD25 200 µg/ml PC61 Biolegend 
LEAF Purified  α-mouse CD210 (IL-
10R) 
200 µg/ml/ 
250 µg/ml 
1B1.3A Biolegend 
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2.1.8  Kits 
BD Cytometric Bead Array (CBA) Mouse Th1/Th2/Th17 Cytokine Kit 
Containing:      Assay Diluent 1 bottle, 30 mL 
Mouse IFN-γ capture beads 
Mouse IL-2 capture beads 
Mouse IL-4 capture beads 
Mouse IL-6 capture beads 
Mouse IL-10 capture beads 
      Mouse IL-17 capture beads 
Mouse Th1/Th2/Th17 cytokine standards 
Mouse Th1/Th2/Th17 PE detection reagent  
Mouse TNF capture beads  
Wash buffer 1 bottle, 130 ml 
Green DYE Master Mix (P.J.K., Germany) 
Containing      2 x master mix 
 
RETROscript  kit (Ambion, Germany) 
Containing:  Control Template RNA 
  10 x RT Buffer 
  10 x PCR Buffer 
  dNTP mix (2.5mM) 
  Random Decamers (50µM) 
  Oligo(dT) Primers  (50µM) 
  MMLV-RT (100 units/µl) 
  RNAse Inhibitor (10 units /µl) 
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  Control PCR primers (5µM) 
  High resolution gel loading solution (5x) 
  Nuclease-free water 
  
RNeasy Mini Kit (Qiagen, Germany) 
Containing:     RNeasy mini spin columns 
      Collection tubes (1.5ml and 2ml) 
      Buffer RLT 
Buffer RW1 
Buffer RPE (concentrate) 
      RNase-free water 
 
2.1.9 Anaesthetic 
Ketamine/ Xylazine (K/X)   Ketamine 100 mg/ml 
Xylazine 3 mg/ml  
 
2.1.10 Parasite strains 
Plasmodium berghei ANKA cl15cy1  Hall et al 2005 [254] 
 
2.1.11  Cell lines 
Human hepatocarcinoma (HuH-7) cells   Nakabayashi et al 1982 [255] 
 
2.1.12 Mouse strains 
NMRI Rjttan, outbred mice   Janvier, France 
Charles River, Germany 
C57BL/6 JRi, inbred mice   Janvier, France 
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      Charles River, Germany 
IL-10-/- /IL-10tm1Cgn mice   gift from the University of Bonn;  
[256] (129/Ola x C57BL/6 genetic background) 
 
2.1.13  Mosquito strain 
Anopheles stephensi     Nijmegen, Netherlands/Berlin, Germany 
 
2.1.14 Oligonucelotides    Invitrogen, Germany 
(as reported by Friesen et al 2010) [121]  
Primers were ordered from Invitrogen as custom DNA oligonucleotides, dissolved in H2O to 
100µM and stored at -20°C.  
 
P. berghei  18S rRNA GenInfo Identifier 160641:  
Forward 5’ AAGCATTAAATAAAGCGAATACATCCTTAC – 3’ 
Reverse 5’ – GGAGATTGGTTTTGACGTTTATGTG – 3’ 
 
Mouse GAPDH GenInfo Identifier 281199965: 
Forward 5’ – CGTCCCGTAGACAAAATGGT – 3’ 
Reverse  5’ – TTGATGGCAACAATCTCCAC – 3’ 
 
2.2 Methods 
2.2.1 Anopheles  methods 
2.2.1.1 Breeding of Anopheles  s tephensi  
Four days following blood-meal, eggs were collected from filter paper placed within a petri dish 
containing 0.1% salt solution. Eggs were washed 1x in 70% ethanol and 2x in 0.1% salt solution. 
Eggs were transferred to trays containing 0.1% salt solution until hatching into larvael forms 
Materials and Methods   
 41  
occured. Larvae were fed with pieces of commercially available dry cat food and relocated into 
fresh salt solution every third day. Nine days post blood-meal larvae transform into pupae and 
hatch into mosquitoes. Mosquitoes were collected and transferred to cages. Mosquitoes were 
infected with P. berghei by being permitted to feed on an infected mouse with blood-resident 
exflagellating gametocytes (described below). P. berghei infected mosquitoes were maintained at 
80% humidity and 21°C with a 12 hour light/dark cycle. Three cotton wool pads saturated with 
10% sucrose soution supplemented with 20 µg / ml para-aminobenzoic acid and 0.1% salt 
solution were placed on top of mosquito cages as mosquito food. Pads were refreshed every 
three days. 
 
2.2.1.2  Anopheles  infection 
Anopheles stephensi mosquitoes were infected with P. berghei clone cl15cy1 [257] by feeding for 15 
minutes on an infected mouse with exflagellating gametocytes at 2 x 24 hour intervals. Infected 
mosquitoes were kept under defined conditions of 80% humidity and 21-24°C. Sporozoites were 
dissected from mosquito salivary glands at day 17 post infection. 
 
2.2.1.3 Examination of infection rate (prevalence) 
Oocysts develop on the midgut basal lamina 10 days post-blood meal. Ten Anopheles mosquitoes 
were anaesthetized on ice and and midguts isolated in RPMI supplemented with 3% BSA via a 
binocular microscope.  Midguts were prepared for examination on glass slides under glass cover 
slips and examined by light microscopy at 40x magnification with phase contrast. Oocyst number 
was calculated per mosquito to indicate the number of infected mosquitoes and yield the 
infectivity rate per mosquito. 
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2.2.1.4 Isolation and determination of the number of salivary gland sporozoites 
Seventeen to twenty four days post-blood meal, Anopheles mosquitoes were anaesthetized on ice 
and salivary glands were isolated in PBS. Salivary glands were homogenized by grinding action 
with a pestle in a 1.5 ml microfuge tube. The homogenate was subjected to centrifugation at 
1000rpm for 3 minutes at 4°C, the supernatant was transferred into a new tube and the pellet re-
suspended in PBS and subject to further homogenization and centrifugation at 1000rpm. The 
second supernatant was pooled with the first and isolated sporozoites counted in a Neubauer 
haemocytometer. Sporozoite number is calculated by the formula 10000(x/y) to give number of 
sporozoites per mililitre where x is the number of sporozoites per quadrate and y is the number 
of quadrats counted. For accuracy, four quadrats were counted in total. 
 
2.2.2 Rodent Methods 
2.2.2.1 General  
All animal experiments were performed according to European regulations and approved by the 
state authorities (Regierungspräsidium Karlsruhe). For all experiments, C57BL/6 mice were 
purchased from Janvier, France and kept under specified pathogen-free (SPF) conditions within 
the animal facility at Heidelberg University (IBF). Animals were matched for sex and age (female, 
6-8 weeks old). For in vivo experiments compounds were administered to groups of C57BL/6 
mice by either intraperitoneal (IP) or subcutaneous (SC) injection at stated concentrations at days 
-2, -1, and 0. 10,000 infectious salivary gland sporozoites were inoculated at day 0 by intravenous 
injection into the tail vein 1h after the final compound injection (Appendix 2). Parasitemia was 
monitored by daily blood smear and Giemsa stain.  
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2.2.2.2 Anaesthesia of malaria-infected mice 
Experimental animals were anaesthetized by intraperitoneal injection of 80 µl 
Ketamine/Xylazine. Animals were placed on mosquito cages for 15 minutes and 4 day-old 
mosquitoes permitted to feed.  
 
2.2.2.3 Rapid Murine Coma and Behavior Scale (RMCBS)  
To determine ECM pathology in C57BL/6 mice, animals were assessed for ten parameters of 
cerebral symptoms as described previously [150], such as coordination and motor performance, 
and scored 0 to 2, where a 0 score correlates with lowest function and 2 the highest. Animals 
were assessed daily and scored from 0 to 20 according to this scale (Appendix 2).  
 
2.2.2.4 Evans Blue Quantification 
Quantification of vascular leakage was performed as described previously [234]. Briefly, mice 
were injected intravenously with 150 µl of 1.5 % Evans Blue (Sigma-Aldrich) and sacrificed 2 h 
later with brains isolated in formamide at 48 h to assess vascular leakage. Absorbance was 
measured at 620 nm in an ELISA reader with Evans blue concentration assessed automatically by 
Magellan V 5.0 software via standard curve starting at 400mg/ml and expressed as mg dye per 
gram of brain tissue. 
 
2.2.2.5 Histology  
(conducted by Dr. Felix Lasitschka, Institute of Pathology, Heidelberg University Hospital) 
 
Histological analysis was performed as described previously [258]: Brains were removed after 
death and snap-frozen in liquid nitrogen. 10-µm thick coronal sections were cut on a cryotome 
(Leica Microsystems, Austria) and mounted on SuperFrost/Plus slides (Microm International, 
Germany). Serial sections were stained with eosin and haematoxylin (Thermo Fisher Scientific, 
Waltham, MA, USA) and Giemsa (Thermo Fisher Scientific). Slides were blinded and three 
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randomly selected sections per coronal plane were subjected to histological analysis. 
Examinations were done on an Olympus BX45 research microscope (Olympus, Japan). 
Visualization by haematoxylin/eosin was achieved by immersing slides in haematoxylin for 60 
seconds to stain the nucelus, followed by a quick washing step with distilled water to remove 
excess dye, a quick immersion in 2% acetic acid to differentiate nuclear staining, 60 seconds 
immersion in distilled water to produce blue nuclear staining, counterstaining by 5 second 
immersion in alcoholic eosin (15g eosin, 2000ml 70% ethanol, 10ml acetic acid), colour 
differentiation by sequential immersion in 2 x 70% ethanol, 2 x 96% ethanol and 2 x 100% 
ethanol until the sections appeared transparent, immersion in xylol for 5 minutes before sections 
were mounted with Consul Mount.  
 
2.2.3 P. berghei  Methods 
2.2.3.1 In vi tro  parasite inhibition assays 
 Exoerythrocytic stages were cultivated in a standard experimental system as previously described 
[259]. One day prior to sporozoite infection, 8-well chamber slides (Nunc) were plated with 3 x 
104 HuH-7 cells and cultured to confluency at 37°C. Purified sporozoites suspended in complete 
medium were added to the chambers and permitted to invade for 90 min. Medium was refreshed 
and supplemented with 1µM-10 nM of the 8-aminoquinolines indicated. Thereafter, medium was 
refreshed daily.  
 
2.2.3.2 Microscopical demonstration of P. berghei  infection using Giemsa staining 
The tail vein was pricked with a needle and a drop of blood smeared onto a glass slide. After the 
smear had dried, it was fixed in 100% methanol for 30 seconds, dried, and then stained in fresh 
10% Giemsa solution for 30 minutes. Slides were washed in water, permitted to air dry and then 
analysed by light microscopy at 100x magnification with oil immersion. Parasitemia was 
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quantified by counting the number of infected red blood cells relative to the number of 
uninfected. A minimum of 5 fields were counted for accuracy. 
 
2.2.4 Cell Biological Methods 
After 24 or 48 h liver-stage development, parasites were fixed with 100% ice cold methanol for 
10 minutes, washed with PBS / 1 % FCS followed by a 15 min blocking step with PBS / 10 % 
FCS at 37°C. Liver stages were visualized using hybridoma culture supernatant anti-HSP70 
antibody [253] and 1:1000 Alexa Fluor 488 goat anti-mouse (Invitrogen). Wells were mounted 
with 10 % glycerol in PBS and embedded with nail varnish. Experiments were conducted in 
triplicate and all liver stages counted per well. Statistical significance was assessed by one-way 
ANOVA with bonferonni post-hoc adjustment. 
 
2.2.5 Cell Culture 
2.2.5.1 Maintenance of human hepatocarcinoma (HuH-7) cells  
Cells were stored in liquid nitrogen in 20% DMSO, 80% FCS. To bring cells into culture from 
frozen stocks, cell stocks were placed in a 37°C water bath and, once thawed, cell suspensions 
were transferred to 15ml DMEM culture media supplemented with 10% FCS and 1% 
penicilin/streptomycin. Cells were subject to centrifugation at 200 x g and resuspended in 
DMEM culture media supplemented with 10% FCS and 1% penicilin/streptomycin within a 
25cm2 gas-permeable culture flask. Cells were maintained at 37°C and 5% CO2 until confluence. 
Cells were “split” for cell culture maintenance by removing the media, washing with HBSS, and 
incubating cells in 0.25% Trypsin/EDTA (Gibco) for 5 minutes to cause detachment. Cells were 
transferred to a 50ml tube and subject to centrifugation at 200 x g for 5 minutes, the pellet 
washed with HBSS and resuspended in 15ml DMEM culture media supplemented with 10% FCS 
and 1% penicilin/streptomycin. A 1ml aliquot from this suspension was then transferred to a 
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new 25cm2 culture flask with culture media to maintain the cell culture. Cells were prepared for 
frozen stocks by resuspending cells in freezing solution (20% DMSO 80% FCS) and transferring 
them to -80°C for 24 hours, followed by storage in liquid nitrogen. 
 
2.2.5.2 Calculation of cell number 
Following trypsinization of cells, a small aliquot (2µl) was diluted in trypan blue to permit 
determination of live and dead cells. Live cells were counted within four large fields and 
calculated by the formula 10000 (x/y) to give number of viable cells per mililitre where x is the 
number of sporozoites per quadrat and y is the number of quadrats counted. For accuracy, four 
quadrats are counted. 
 
2.2.7 Chemistry Methods 
2.2.7.1 General  
 All solvents were distilled before use. Commercially available material was used without further 
purification. NMR spectra were recorded on a DMX 600 instruments. Assignments of the NMR 
signals were performed using Dept, COSY, HSQC and HMBC. IR spectra were recorded on a 
Jasco-FT-410-spectrometer with wavelength (ṽ) reported in cm-1. High resolution MS 
(HRESIMS) was performed on a Bruker Daltonik microTOF spectrometer. Reactions were 
routinely monitored by thin-layer chromatography (TLC) using pre-coated plates (Silica Gel 60, 
F254, Merck) and visualized by UV light. Detection of the compounds was achieved using the 
ninhydrin stain. Flash column chromatography was carried out using deactivated (7.5 % of 
ammonia) Silica Gel 60 (0.032-0.063 mm particle size, Merck). Primaquine was obtained from 
commercially available primaquine bisphosphate by extraction of the compound as a free base 
from an aqueous solution of sodium hydrocarbonate by dichloromethane. 
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2.2.7.2 N1-isopropyl-N4-(6-methoxyquinolin-8-yl)-pentane-1,4-diamine (isopentaquine) 
synthesis  
(Conducted by Eleonora Paulsen, Department of Organic Chemistry, University of Copenhagen) 
The free base of primaquine (846 mg, 3.262 mmol, 1 equiv) in dry methanol (15 mL) was added 
to acetone (960 μL, 13.048 mmol, 4 equiv). The mixture was stirred at room temperature 
overnight before sodium borohydride (370 mg, 9.782 mmol, 3 equiv) was added in small portions 
and the mixture was stirred for additional 15 hours. The crude was filtered and concentrated 
under reduced pressure. Purification by column chromatography with 
dichloromethane/methanol 50:1 as an eluent yielded the desire product as a yellow oil. 
 
2.2.7.3 Compound preparation 
For all in vitro studies, compounds were dissolved in dimethyl sulfoxide (DMSO) to a stock 
concentration of 0.02 M and further diluted where required by serial dilution in complete cell 
culture medium (DMEM, 10% heat inactivated FCS, 1 % pen/strep). Final DMSO concentration 
was always <0.01%. For all in vivo studies, compounds were dissolved in DMSO to produce a 
stock concentration of 0.2 mg/µL. The stock concentration was further diluted in sterile PBS 
with 4 % Cremophor RH 40 (BASF) to the final concentrations stated. 
 
2.2.8 Molecular Biological Methods 
2.2.8.1 Isolation of RNA with RNeasy Mini Kit 
Cells were disrupted by the addition of 350µl RLT lysis buffer with 1% β-mercaptoethanol 
(14.3M). The mixture was vortexed for 60 seconds and total RNA isolated from the cell lysate as 
per the manufacturer’s instructions. The cell lysate was homogenized in buffer to ensure 
inactivation of RNAses and applied to a RNA-binding membrane spin column in the presence of 
ethanol. Isolated RNA was eluted in distilled water and stored at -80°C. 
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2.2.8.2 DNase treatment of RNA 
Following RNA isolation with the RNeasy Mini Kit, contaminating DNA was digested by the 
addition of DNase. Isolated RNA was mixed with 1µl TURBO DNase and 1/10 volume 10 x 
TURBO DNase buffer and incubated at 30°C for 30 minutes. The reaction was stopped by the 
addition of 1/10 DNase Inactivation Reagent and incubation at room temperature for 2 minutes. 
The mixture was subject to centriguation for 1 minute at 10,000 x g and the supernatant 
(containing the RNA) transferred to a fresh tube. 
 
2.2.8.3 RNA Integrity 
Concentration and contamination of isolated RNA was assessed via a NanoDrop 
spectrophotometer.  Only those RNA samples with a 260/280 ratio >1.8 were utilized. 
 
2.2.8.4 First strand cDNA synthesis with Fermantas “First Strand cDNA Synthesis Kit” 
cDNA reverse-transcription from RNA was achieved according to the manufacturer’s manual. 
5µl of isolated RNA was mixed with 0.5µl random decamer primers, 0.5µl oligo dT primers. 
After mixing, the mixture was subjected to incubation at 72°C for 3 minutes, cooled on ice and 
1µl RT buffer, 2µl dNTP, 0.5µl RNAse inhibitor and 0.5µl reverse transcriptase was added. This 
mixture was then homogenized, briefly centrifuged and subject to incubation at 42°C for 1 hour 
and 92°C for 10 minutes. 
 
2.2.8.5 Quantitive RealTime PCR (QRT-PCR) 
Quantification of parasite liver loads by quantitative real-time PCR was conducted as previously 
described [121, 260]. Briefly, mice were killed 42 h after sporozoite infection and livers were 
removed, homogenized and subjected to RNA isolation via the RNeasy kit (Qiagen) with 
complementary DNA (cDNA) synthesized by the First strand cDNA Synthesis kit (Fermentas) 
Materials and Methods   
 49  
as per manufacturer’s instructions. qRT-PCR was conducted with the ABI 7500 (Applied 
Biosystems) and Green DYE Master Mix (P.J.K.) using gene-specific primers for the P. berghei 
18S rRNA and the mouse GAPDH gene. Samples were analysed in triplicate on 96-well plates. 
Samples were incubated with an activation step of 95°C for 10 minutes, followed by 15 seconds 
denaturation at 95°C, 15 seconds annealing at 55°C and 45 seconds extension at 60°C. The three 
latter steps were repeated for 40 cycles. Fluorescence data was collected during the extension 
phase. Following amplification, a melting curve to test for false positive signals caused by primer 
dimers was performed, consisting of a gradient from 55°C to 95°C increasing by 1°C steps. 
Relative copy numbers were determined via the ΔCt method where housekeeper GAPDH values 
were substracted from 18srRNA values and the mean calculated [260]. Statistical significance was 
determined on ∆Ct values by student’s t test. Asterisks signify degrees of significance where *** 
indicates P < 0.001, ** indicates P = < 0.01, * indicates P  < 0.05 and “ns” indicates P >0.05. 
 
2.2.9 Immunological methods   
2.2.9.1 Cytokine Bead Array Analysis 
 Cytokine Bead array analysis was performed according to the manufacturer’s protocol using a 
Th1/Th2/Th17 CBA kit (BD Biosciences). For analysis of cytokine concentration, organ 
homogenates were isolated at the designated timepoint post-infection. Briefly, the liver was gently 
pressed through an iron mesh sieve, washed with 1x PBS containing 2 mM EDTA and 1% FCS 
and subject to centrifugation at room temperature at 1500rpm for 10 min. Supernatants were 
stored at -20°C in protease inhibitor cocktail (1 x protease inhibitor (Roche), 0.05 % Tween 20 in 
PBS) for cytokine analysis. Organ homogenates and serial dilutions of cytokine standards were 
incubated with 50 µl of beads diluted in dilution buffer. PE-detection reagent mix was added and 
samples were incubated for 2 h in the dark. Samples were subsequently washed in wash buffer, 
300 events/cytokine were acquired on a FACSCalibur, gating on the total bead population 
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identified by FSC-SSC profile. Cytokine concentrations were analysed by FCAPArray software 
version 2.0 (BD Biosciences). 
 
2.2.9.2 Flow Cytometry 
For flow cytometry analysis of intracellular cytokines, T, DC and NK cells, mice were 
anaesthetized and perfused intracardially with 20ml 1xPBS. Organs were prepared as single cell 
suspensions via homogenization through a 70 µm cell strainer in PBS. Liver lymphocytes were 
isolated by resuspension in 70 % percoll and collected in the cell pellet after centrifugation at 
2000 rpm. Cells were then subjected to erythrocyte lysis in erythrocyte lysis buffer for 15 minutes 
at room temperature. Cells were then washed and counted in a hemocytometer. For 
multifunctional T-cell analysis, cells were stimulated ex vivo with 1 µM ionomycin (Sigma-Aldrich) 
and 50 ng/ml PMA (Sigma-Aldrich) with 10 µg/ml Brefeldin A to inhibit Golgi function for 5 h 
at 37°C. Afterwards, and where cells were not stimulated, cells were stained and analysed for 
expression of CD8a, CD4, CD44, CD62L, CD25, CD69, CD3, CD11c and NK1.1 markers. For 
intracellular staining, after surface staining cells were fixed in 2 % PFA, washed, permeablized 
with 0.2 % saponin lysis buffer and stained for intracellular cytokines TNF-α (clone: MP6-
XT22/APC, eBioscience), IFN-γ (clone: XMG1.2/FITC, eBioscience) and IL-2 (clone: JES6-
5H4/PE, eBioscience). Data was collected on a FACSCanto and analysed by CellquestPro 
software (BD Biosciences). Brain leukocyte isolation was conducted by cutting brains into pieces 
and digesting in 0.5 mg/ml Collagenase A (Sigma-Aldrich) at 37°C for 30 min. Organs were 
subsequently passed through an iron mesh sieve to obtain a single cell suspension. Cells were 
pelleted and resuspended in 3 ml 30 % Percoll underlayed by 3 ml 37 % and 3 ml 70 % Percoll. 
Cells were centrifuged at 2000 rpm for 20 min at room temperature and cells were collected from 
the interphase.  
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2.2.9.3 Depletion experiments 
IL-10-receptor depleting antibody, clone 1B1.3A was purchased from Biolegend, USA and 
administered intraperitoneally at 250 µg at either day -1 or 5 as indicated in the results (-1 to 
deplete IL-10 during liver stage development, 5 to deplete IL-10 at fulminant infection) and 200 
µg daily thereafter until the endpoint of the experiment. CD8+ T cell depleting antibody clone 53-
6.7 was purchased from Biolegend, USA and administered 150 µg 3 days prior to the experiment 
commencement and every 3 days thereafter until the endpoint of the experiment. Anti-CD25 
depleting antibody clone PC61 was purchased from Biolegend, USA and 250 µg administered 
intraperitoneally 8 days prior to sporozoite inoculation to deplete those cells expressing CD25, 
expressed on activated T and B cells, thymocyte subsets, pre-B cells and regulatory T cells 
(Biolegend: www.biolegend.com) [261, 262]. 
 
2.2.9.4 Isolation of splenocytes 
Sacrificed animals were dissected and spleens isolated in 2 ml PBS. The organ was homogenized 
through a cell strainer with the plunger from a 5 ml syringe and the suspension centrifuged at 
1500 rpm for 5 minutes at  4°C. The cells were then resuspended in 2 ml erythrocyte lysis buffer 
for 15 minutes at room temperature. 2 ml PBS was then added to stop osmotic lysis and the cells 
resuspended in 2 ml PBS. Cells were then diluted 1:200 in trypan blue to differentiate between 
live and dead cells and live cells were quantified using a hemocytometer. 2x106 cells were seeded 
into 1.5ml reaction tubes in 200 µl PBS, stained immediately with fluorescent antibodies and 
analysed by flow cytometry or resuspended in growth medium and cultured at 95% humidity, 
37°C and 5% CO2 overnight. 
2.2.9.5 Isolation of liver-infiltrating lymphocytes 
Sacrificed animals were dissected and livers isolated in 2 ml PBS. Similarly as for the spleen, the 
liver was homogenized with the plunger from a 5 ml syringe and the suspension centrifuged at 
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1500 rpm for 5 minutes at  4°C. The cells were resuspended in 14 ml percoll mixture consisting 
29.1ml HBSS, 14.2ml percoll, 1.6ml 10x PBS and subjected to 2000rpm centrifugation without 
brake. Liver infiltrating lymphocytes are located in the pellet, with fatty tissue and debris 
suspended above. The cells were then resuspended in 2-5 ml erythrocyte lysis buffer for 15 
minutes at room temperature. 2ml PBS was then added to stop osmotic lysis and the cells 
resuspended in 2ml PBS. Cells were then diluted 1:200 in trypan blue to differentiate between live 
and dead cells and live cells were quantified using a hemocytometer. As with splenic lymphocyte 
isolation above, 1- 2x106 cells were seeded in 200 µl PBS, stained immediately with fluorescent 
antibodies and analysed by flow cytometry or resuspended in growth medium and cultured at 
95% humidity, 37°C and 5% CO2 overnight. 
 
2.2.9.6 Isolation of brain-infiltrating lymphocytes 
The brain was isolated from sacrificed mice, cut into pieces, suspended in 0.05% collagenase and 
incubated at 37°C, 5% CO2 and 95% humidity for 45 minutes. The cells were homogenized by 
passing the solution through a syringe multiple times and by being passed through an iron mesh 
sieve. Cells were centrifuged for 8 minutes at 1500rpm and resuspended in 7ml 70% percoll, 
layered with 6ml 30% percoll on top. This two-gradient percoll step was subjected to 
centrifugation for 25 minutes at 2000rpm and the cells isolated from between the two percoll 
layers (fig 2.1). After centrifugation for 8 minutes at 1500 rpm, cells were resupended in 0.3 ml 
PBS and a 1:100 dilution made in 1:10 trypan blue (diluted in distilled water) and counted in a 
hemocytometer.  
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2.2.10 Statistical Analysis 
Statistics calculated by one-way ANOVA with Bonferonni post-hoc adjustment and student’s T 
test. Asterisks signify degrees of significance where *** indicates P < 0.001, ** indicates P = < 
0.01, * indicates P  < 0.05 and “ns” indicates P >0.05. 
 
Figure 2.1 Brain-infiltrating lymphocyte isolation from the interphase following percoll gradient 
centrifugation. 
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Chapter 3 
Results 
3.1  Isopentaquine and primaquine administration causes inhibition of P. berghei  liver 
stage development in v i tro 
To test for a potential inhibitory effect on parasite liver stage development by 8-aminoquinolines, 
isopentaquine, pamaquine, primaquine and a hybrid of chloroquine-primaquine (synthesized by 
Melanie Diegel, University of Wuerzburg) were administered to in vitro cultures of immortalized 
human hepatoma cell lines infected with P. berghei sporozoites. Compounds were administered to 
the culture media some two hours after the addition of sporozoites, so that any parasite 
inhibition due to the compound would specifically effect the liver stage development, rather than 
sporozoite motility or liver cell invasion. Liver stage development was stopped after 24 and 48 
hours and numbers of liver stage parasites were counted by immunofluorescence microscopy as a 
measurement of the inhibition of liver stage development.  Although not statistically significant, 
there was a notable decrease in numbers of liver stages at 48 hours in cultures containing both 
isopentaquine and primaquine (fig 3.1). In addition, liver stages cultured in the presence of these 
compounds showed an altered morphology to those cultured in the absence of compound. This 
indicates that these compounds had an effect on attenuating liver-stage development  
 
3.2 Isopentaquine and primaquine administration causes inhibition of P. berghei  
ANKA-induced cerebral malaria development in v ivo 
In light of this finding, isopentaquine and primaqine were selected based on their liver-stage 
attenuating effect and were administered in vivo at sub-therapeutic concentrations by different 
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Figure 3.1. Isopentaquine and primaquine administration causes inhibition of P. berghe i  liver 
stage development in v i tro  Confluent HuH-7 cell cultures were infected with 30,000 P. berghei ANKA 
sporozoites. After two hours, cultures were incubated with 8-aminoquinoline compounds as indicated at 
1µM, 100nM or 10nM. Control substances were administered at 10µM final concentration (standard 
inhibitory concentration). Untreated wells were given culture medium alone. After either 24 or 48hrs, cells 
were stained with anti-HSP70 antibody and parasite numbers per well measured by microscopy. Statistical 
significance was calculated by one-way ANOVA with Bonferonni post-hoc adjustment. In all cases p = 
>0.05 
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routes (intraperitoneal and subcutaneous injection) to determine their tolerance by experimental 
animals and the effect of infection on cerebral pathology. I hypothesized that chemical 
attenuation during liver stage development may lead to a change in disease outcome.  Primaquine 
was well-tolerated by mice at 60mg/kg and no cytotoxic effects were observed (defined as 
abnormal motor and grooming behaviour, weight loss, change in diet or sleeping habits) and 
intriguingly, by the intraperitoneal route of administration, mice did not develop cerebral 
symptoms as measured by the rapid murine coma and behaviour scale [150] (Appendix 1).  
 
Isopentaquine proved to be cytotoxic at 60mg/kg by both intraperitoneal and subcutaneous 
administration and experiments were discontinued (table 3.1). At 30mg/kg, isopentaquine caused 
mild and limited cytotoxic symptoms by intraperitoneal administration (altered motor and 
grooming behaviour lasting several hours) and experiments were similarly discontinued, although 
these mice did not develop cerebral symptoms. No cytotoxic effect was apparent, however, by 
subcutaneous administration of isopentaquine, and animals were protected against cerebral 
symptoms (Table 3.1). 
 
Table 3.1. Primaquine and isopentaquine administration by different routes and their 
cytotoxic effect and influence on the development of cerebral pathology. 
Animals were administered isopentaquine or primaquine at varying concentrations administration routes 
as indicated at days -2, -1 and 0. Treated animals and control mice were injected intravenously with 10,000 
PbANKA salivary gland sporozoites at day 0. Cytotoxicity was determined qualitatively (abnormal motor 
and grooming behaviour, weight loss, change in diet or sleeping habits) and cerebral malaria was 
determined as either positive or negative by quantitative analysis via the RMCBS scale. 
Compound 
 
Administration 
Route 
Concentration Cytotoxic 
Behaviour 
Cerebral Symptoms 
(# animals) 
Isopentaquine IP 60mg/kg Y 2/10 
Isopentaquine SC 60mg/kg Y 0/10 
Isopentaquine IP 30mg/kg Y 0/10 
Isopentaquine SC 30mg/kg N 0/10 
Primaquine IP 60mg/kg N 0/10 
Primaquine SC 60mg/kg N 8/10 
None - - N 9/10 
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It is important to note that while all experimental mice treated with primaquine and 
isopentaquine did not develop cerebral symptoms, they developed patent blood-stage 
parasitemia.  In a head-to head comparison between the different administration routes that did 
not cause cytotoxic effects, animals administered both isopentaquine by the subcutaneous route 
and primaquine by the intraperitoneal route developed hyperparasitemia-associated anaemia and 
died after day 15 post-infection. However, those animals treated with isopentaquine developed 
higher parasitemias and died at later time points than those treated with primaquine (fig 3.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Outcome of isopentaquine and primaquine treatment on blood-stage parasitemia in 
v ivo . Animals were administered isopentaquine at 30mg/kg or primaquine at 60mg/kg by either 
subcutaneous or intraperitoneal injection at days -2, -1 and 0. Treated animals and control mice were 
injected intravenously with 10,000 PbANKA salivary gland sporozoites at day 0. Parasitemia was 
determined by giemsa-stained blood smears. 
 
 
3.3  Experimental animals subjected to chemical attenuation with isopentaquine 
sustain high parasitemias, die from hyperparasitemia-associated anaemia and do not 
develop experimental cerebral malaria. This model of attenuation is hereafter termed 
“Negated Cerebral Malaria” (NCM). 
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Due to it causing a favourable outcome of infection (absence of cerebral pathology, prolonged 
period until death of approximately 16 days), the subcutaneous administration of isopentaquine 
at 30mg/kg was selected as the best means by which to alter the outcome of ECM by chemical 
attenuation. This model consists of three sub-therapeutic doses of isopentaquine prior to 
intravenous infection of 10,000 Plasmodium berghei ANKA (PbANKA) salivary gland sporozoites 
(appendix 2). All mice became patent but did not show any typical cerebral symptoms, as 
measured by the RMCBS scale described previously [150]  but the onset of patency was delayed 
by 3-4 days (fig 3.3). Furthermore these mice did not show any typical cerebral symptoms. This 
negated-cerebral-malaria (NCM) outcome was characterized by death from hyperparasitemia-
associated anaemia at day 25-30 post-infection. 
 
 
Figure 3.3. Outcome of chemical attenuation on blood-stage parasitemia and cerebral pathology. 
Animals were subjected to chemical attenuation (NCM) and uninfected control mice (Control) were 
subcutaneously injected with 30 mg / kg isopentaquine at days -2, -1 and 0. Animals subjected to chemical 
attenuation and positive control (ECM) mice were injected intravenously with 10,000 PbANKA salivary 
gland sporozoites at day 0 and chemically attenuated mice (n = 5) were infected with 10,000 PbANKA 
sporozoites. Parasitemia was determined by blood smear and Giemsa staining (left panel, with inset figure 
zoomed into days 0-10) and their behaviour scored from 0 - 20 according to the Rapid Murine Coma and 
Behaviour Scale (RMCBS) (right panel). 
 
The brain is the centrepiece of ECM pathology. To determine if mice subjected to chemical 
attenuation were free of the clinical manifestations of ECM within the brain, and not only 
appearing outwardly healthy, we assessed the brain for indicators of pathology by evaluating the 
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integrity of the blood-brain barrier and by quantifying the number of infiltrating lymphocytes 
present in the organ. ECM pathology is associated with blood-brain barrier damage and 
haemorrhage, oedema and sequestration of parasitized erythrocytes and lymphocytes in the brain 
microvasculature. To ascertain whether mice subjected to chemical attenuation bear any of these 
hallmarks of ECM pathology, histological analysis was performed on cryosections of brain tissue 
isolated from chemically attenuated, positive and negative control mice at day 8 post-infection. 
Positive control mice that developed ECM featured clear signs of pathology, such as 
subarachnoidal bleeding, leukocyte infiltration and adherence of leukocytes to venule walls with 
associated accumulation of malaria pigment (fig 3.4) No such symptoms were evident in 
chemically attenuated mice, however, with the NCM phenotype consistent with an absence of 
leukocyte infiltration in cerebral blood vessels and intact epithelial walls (fig 3.4). 
 
Since ECM is associated with leukocyte sequestration in the brain [147, 154, 173, 220, 263] I 
quantified CD8+ and CD4+ T cells from the brains in animals displaying ECM and NCM 
phenotypes. Interestingly, NCM mice showed dramatically fewer CD8+ infiltrates, but a 
comparable number of CD4+ infiltrates (Fig 3.5). This correlates with the observation that CD8+ 
T cells in the brain-sequestered leukocytes are essential for the cerebral symptoms and mortality 
in ECM [217].  
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Figure 3.4. Animals subjected to chemical attenuation show absence of pathology by histological 
examination at the timepoint post-infection that control mice are in coma. Test animals (NCM) 
were subjected to chemical attenuation and both NCM and control animals (ECM) infected with 10,000 
PbANKA sporozoites. Sections were isolated from brain tissue, stained with haematoxylin and eosin and 
analysed for indicators of cerebral pathology. Representative slides with arrowheads point to incidences of 
subarrachnoidal bleeding and haemorrhaging in the ECM panel, and a vessel absent from lymphocyte 
sequestration and an intact epithelium in the NCM panel. Analysis performed by Felix Lasitschka, 
Institute of Pathology, University Hospital Heidelberg. 
 
To assess the integrity of the vascular endothelium in experimental animals, evans blue dye was 
injected into experimental animals at day 8 post-infection, the time point at which control mice 
succumbed to cerebral symptoms. Upon injection of Evans Blue, BBB disruption leads to 
extravasation of dye into the brain tissue, which can be visualized and assessed quantitatively and 
qualitatively. Control animals that developed ECM displayed evidence of cerebral pathology: a 
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dark, evenly distributed staining, compared to very faint staining in brains from chemically 
attenuated NCM animals (fig 3.6) that was not statistically significantly different to naïve brains 
  
 
 
 
 
 
 
 
 
Figure 3.5. Animals subjected to chemical attenuation show absence of brain-infiltrating 
lymphocytes by flow cytometry analysis at coma Whole number cerebral CD8+ and CD4+ T cell 
infiltration at day 8 post-infection was analysed by flow cytometry in animals subjected to chemical 
attenuation and protected from ECM (NCM), untreated controls (ECM) and uninfected but chemically 
attenuated controls (Control). Representative dot blot indicates CD4 vs CD8 cell distribution in mice 
presenting ECM and NCM phenotypes. 
 
from non-infected animals by colourimetric analysis (fig 3.6), indicating that the BBB and 
vascular endothelium remained intact in animals subjected to chemical attenuation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Animals subjected to chemical attenuation do not feature blood-brain barrier 
permeabilization. Animals (groups of 5) were assigned to ECM, NCM and control groups as described, 
and infected with 10,000 PbANKA sporozoites and sacrificed at day 8 post-infection. Evans Blue 
extravasation in formamide at day 8 post-infection was compared between chemically attenuated and 
ECM control mice by visual appearance. Statistics calculated by one-way ANOVA with Bonferonni post-
hoc adjustment. Asterisks signify degrees of significance where *** indicates P < 0.001, ** indicates P = 
< 0.01, * indicates P  < 0.05 and “ns” indicates P >0.05. 
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Having established that animals subjected to chemical attenuation do not bear any of the 
hallmarks of ECM and that the NCM phenotype is indistinguishable from uninfected mice in 
terms of histology, BBB integrity and animal behaviour, I focussed on the delay in the onset of 
patency that is apparent in NCM. To investigate this delay qRT-PCR analysis of the P. berghei 18S 
rRNA transcript levels were performed. Liver stage development in NCM, characterized by 
multiple nuclear divisions [264], was decreased as shown by quantitative transcriptional analysis at 
48h post-infection (fig 3.7). This is indicative that chemical attenuation causes attenuated growth 
of the parasite pre-erythrocytic development at the liver stage. 
 
Having established that chemical attenuation with isopentaquine causes a delay in the onset of 
patent parasitemia, lower liver loads and absence of cerebral symptoms (the NCM phenotype) I 
next examined if the early host immune response, during which delayed, attenuated liver-stage 
development occurs, is responsible for the protective phenotype in NCM by parasite transfer 
experiments. To investigate whether the absence of cerebral pathology in NCM is due to a 
modification of the parasite at the blood stage I isolated 106 parasitized erythrocytes (pRBC) 
from NCM mice at day 2 post-patency and transferred them by intravenous injection into naïve, 
uninfected animals. All recipient mice suffered clinical symptoms and died of ECM (fig 3.8), thus 
indicating that intra-erythrocytic development after chemical attenuation remains unaffected and 
infected erythrocytes retain their ability to cause ECM. 
 
Furthermore, to determine whether residual isopentaquine affects the parasite at the blood stage 
during patency, animals were subjected to chemical attenuation and challenged intravenously with 
106 parasitized erythrocytes at day 5 post-infection. This protocol was chosen to mimic the onset 
of patency in NCM. However, animals were not protected and succumbed to cerebral pathology. 
Thus the NCM phenotype is only produced when parasites undergo liver stage development in 
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an animal subjected to chemical attenuation and is retained in that animal alone. It was therefore 
assumed that an immune response to the pre-erythrocytic stage is responsible for the protective 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7. Animals subjected to chemical attenuation show decreased transcript abundance of 
parasite-specific 18S rRNA at 42 h post-infection. Animals (groups of 3), assigned to chemically 
attenuated (NCM) and positive control (ECM) mice, were infected with 10,000 PbANKA sporozoites and 
sacrificed at 42 h post-infection. Livers were extracted and RNA isolated and cDNA synthesized. Relative 
liver load calculated via ΔCt analysis based on parasite-specific 18S rRNA transcription. Statistics 
calculated by student’s T test. Asterisks signify degrees of significance where *** indicates P < 0.001, ** 
indicates P = < 0.01, * indicates P  < 0.05 and “ns” indicates P >0.05. 
 
phenotype in NCM and that this pre-patent period, during which delayed, attenuated liver-stage 
development occurs, is crucial for the outcome of ECM.  
 
 
 
 
 
 
 
 
Figure 3.8. The host immune response from the liver induces protection from ECM. Parasitized 
erythrocytes from chemically attenuated mice remain able to induce ECM Left panel) Mice in 
group “iRBC” (groups of 5) were infected with pooled 1 x 106 infected erythrocytes from patent NCM 
mice (groups of 5). Right panel) Mice in group “iRBC” (groups of 5) were subjected to chemical 
attenuation and at day 5 post-attenuation were infected with 1 x 106 infected erythrocytes from pooled 
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infected but untreated mice. 
 
3.4 Cytokine Bead Array analysis reveals an increase in IFN-γ  in the liver tissue and 
serum in experimental animals subjected to chemical attenuation at day 4 post-infection 
Since it was hypothesized that the immune system is responsible for the NCM phenotype and 
that the pre-patent period is a crucial requirement for protection, as described above, the immune 
response prior to patency was analysed. Since IFN-γ and IL-10 are the archetypal Th1 and Th2 
cytokines associated with the two main branches of the cellular immune response, their protein 
concentrations were measured by cytokine bead array analysis in both the liver and serum. I 
observed a remarkable increase in total IFN-γ protein in both the liver and serum at day 4 in 
animals subjected to chemical attenuation compared to ECM control and uninfected control 
mice. This was particularly pronounced in the liver (fig 3.9). 
 
Since IFN-γ is mainly produced by T lymphocytes and to a minor extent by NK and NKT cells, 
flow cytometry analysis was performed on cells isolated from liver and spleen tissue to determine 
T lymphocytes and NK cell numbers. This was followed by intracellular cytokine staining to 
determine their cytokine output. I observed only a minor difference in the NK cell populations in 
these organs and no difference in their IFN-γ cytokine staining (fig 3.10) and therefore concluded 
that these cells are not responsible for the high concentration of IFN-γ characteristic of the 
NCM phenotype. 
 
3.5  Flow cytometry analysis reveals an increase in T effector cells, a decrease in CD25 
and CD69 T cell marker expression and increased cytokine production and Th1 
multifunctionality intrahepatic T cells from experimental animals subjected to chemical 
attenuation at day 4 post-infection ex vivo .  
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Having excluded NKs as the cell type responsible for the high levels of IFN-γ I subjected the 
other typical IFN-γ producing cell, the T lymphocyte, to flow cytometric analysis. I observed a 
higher number of both CD8+ and CD4+CD44hiCD62L- effector memory T cells present in the 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9. Mice subjected to chemical attenuation show elevated IFN-γ  in both liver and serum 
at day 4 post-infection ex vivo . Animals were subjected to chemical attenuation, sacrificed at day 4 post-
infection and their liver and blood serum were harvested and assessed for IFN-γ and IL-10 by cytokine 
bead array analysis. Statistics calculated by one-way ANOVA with Bonferonni post-hoc adjustment. 
Asterisks signify degrees of significance where *** indicates P < 0.001, ** indicates P = < 0.01, * indicates 
P  < 0.05 and “ns” indicates P >0.05. 
 
spleen and a markedly higher number of CD8+CD44hiCD62L T effector cells in the livers of 
animals subjected to chemical attenuation compared to ECM control mice. The increase in this 
subset of T cells corresponded with a pronounced increase in the expression of activation marker 
CD44 on both CD8+ and CD4+ T cells in liver and spleen at day 4 post-infection (fig 3.11). 
Intracellular cytokine staining of the intrahepatic CD8+ and CD4+ T lymphocytes revealed an 
increased number of IFN-γ-positive cells, in addition to IL-2 and TNF-α (fig 3.12). 
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Figure 3.10. Mice subjected to chemical attenuation do not show elevated NK cells or NK-derived 
IFN-γ  in both liver and serum compared to ECM controls at day 4 post-infection. Animals (groups 
of 5) were assigned to ECM, NCM and control groups as described, and infected with 10, 000 PbANKA 
sporozoites and sacrificed at day 4 post-infection. Additionally uninfected control mice were sacrificed. 
Organs were harvested and lymphocytes isolated and stained for NK1.1, CD3 and IFN-γ to determine 
whole number NK cells and whole number NK cells producing IFN-γ. Statistics calculated by one-way 
ANOVA with Bonferonni post-hoc adjustment. Asterisks signify degrees of significance where *** 
indicates P < 0.001, ** indicates P = < 0.01, * indicates P  < 0.05 and “ns” indicates P >0.05. 
 
These liver-derived CD8+ and CD4+ T lymphocytes showed an increase in production of 
multiple pro-inflammatory cytokines and T cell multifunctionality, skewed towards a Th1 
response in NCM (figure 3.10). It was therefore deemed highly likely that CD8+ T cells are 
responsible for the IFN-γ observed in the liver of chemically attenuated mice (fig 3.9). 
 
Multifunctional T cells are CD4+ T cells that simultaneously secrete IFN-γ, IL-2 and TNF-α. 
These cells are associated with Th1 responses and protection from several infections [265]. Cell 
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“multifunctionality” can be measured by the number of cytokines they secrete. Cells can be 
categorized into single, double or triple cytokine producers. In addition, CD8+ T cells can be 
analysed by the same criteria to ascertain Th1-like behaviours. Interestingly, at day 4 post-
infection, spleen-derived CD8+ and CD4+ T lymphocytes in chemically attenuated mice showed 
an increase in production of multiple pro-inflammatory cytokines and T cell multifunctionality, 
skewed towards a Th1 response in NCM (fig 3.13). The NCM phenotype featured 15% triple-
positive CD8+ T cells, compared to 8% in ECM control mice and 23% triple positive CD4+ T 
cells, compared to 14% in ECM control mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11. Animals subjected to chemical attenuation show increased accumulation of T 
effector cells at the liver and spleen, increased CD44 activation. Animals (groups of 5) were assigned 
to ECM, NCM and control groups as described, and infected with 10,000 PbANKA sporozoites and 
sacrificed at day 4 post-infection. Organs were harvested and lymphocytes isolated and stained for CD8, 
CD4 and CD44 and CD62L to determine A) whole number liver effector memory cells 
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(CD8+CD44hiCD62L-); B) whole number splenic effector memory cells (CD8+CD44hiCD62L- and 
CD4+CD44hiCD62L-); C) percentage CD44 expression by CD8+ and CD4+ T cells in liver and D) spleen. 
Upper histograms represent CD8+ T cells and lower histogram CD4+ T cells and are single representative 
samples from whole experimental group. E) Representative dot-blot illustrating gating. Statistics 
calculated by one-way ANOVA with Bonferonni post-hoc adjustment. Asterisks signify degrees of 
significance where *** indicates P < 0.001, ** indicates P = < 0.01, * indicates P  < 0.05 and “ns” 
indicates P >0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12. Liver-infiltrating lymphocytes expressing IL-2, TNF-α  and IFN-γ  are increased in 
animals subjected to chemical attenuation  at day 4 post-infection ex vivo . Animals (groups of 5) 
were assigned to ECM, NCM and control groups as described, NCM and ECM mice were infected with 
10,000 PbANKA sporozoites. Livers were harvested at day 4 post-infection and liverderived lymphocytes 
isolated. Cells were stained for CD8 (A) and CD4 (B), permeabilized and stained for intracellular cytokines 
IFN-γ TNF-α and IL-2. Statistics calculated by one-way ANOVA with Bonferonni post-hoc adjustment. 
Asterisks signify degrees of significance where *** indicates P < 0.001, ** indicates P = < 0.01, * indicates 
P  < 0.05 and “ns” indicates P >0.05. 
 
Given this apparent T cell phenotype in NCM at day 4 post-infection - increased splenic and 
intrahepatic multifunctional effector T cells producing Th1 cytokines – T lymphocytes were 
subjected to further analysis. To assess early T-cell activation in NCM, I examined CD69 and 
CD25 at day 4 post-infection. CD69 is an early lymphocyte activation marker associated with 
active, tissue-invading cells [251] while CD25 forms part of the IL-2 receptor and has been 
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associated with several cell phenotypes, including early T cell activation [266] and regulatory T 
cells. I observed a decrease in CD25 and CD69 expression on CD8+ and CD4+ splenic T cells in 
NCM but not in the liver (fig 3.14). This may indicate decreased priming of splenic T-cells 
destined to migrate to the cerebral tissues in NCM at this stage of infection in contrast to ECM, 
where activation of T cells occurs later after the onset of blood infection. These data suggest that 
early NCM immunopathogenesis features increased accumulation of T-effector cells in both liver 
and spleen and a pronounced Th1-multifunctional environment. 
 
 
Figure 3.13. Animals subjected to chemical attenuation feature elevated T-cell multifunctionality 
at day 4 post-infection. Animals (groups of 5) were assigned to ECM, NCM and control groups as 
described, and infected with 10,000 PbANKA sporozoites and sacrificed at day 4 post-infection. 
Additionally uninfected control mice were sacrificed. Organs were harvested and lymphocytes isolated and 
cultured ex vivo with PMA/Ionomycin and Brefeldin A. Cells were stained for CD8, CD4 and IFN-γ, 
TNF-α and IL-2. IFN-γ positive cells were gated and assessed for their multifunctionality by co-
expression of TNF-α and IL-2, represented by percentage according to whether they express one, two or 
three cytokines. Analysis performed by Jochen Behrends, Research Institute Borstel. 
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Figure 3.14. Animals subjected to chemical attenuation feature decreased expression of CD69 and 
CD25 on their splenic CD8+ T cells at day 4 post-infection. Animals (groups of 5) were assigned to 
ECM, NCM and control groups as described, infected with 10,000 PbANKA sporozoites and sacrificed at 
day 4 post-infection. Organs were harvested and splenic and liver-derived lymphocytes isolated and 
stained for CD8 (A, C), CD4 (B, D), CD69 and CD25. Expression was calculated as percentage activation. 
Statistics calculated by one-way ANOVA with Bonferonni post-hoc adjustment. Asterisks signify degrees 
of significance where *** indicates P < 0.001, ** indicates P = < 0.01, * indicates P  < 0.05 and “ns” 
indicates P >0.05. 
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3.6 Flow cytometry analysis reveals a decrease in T effector cells and CD25 and CD69 
expression on intrahepatic and splenic T cells in experimental animals subjected to 
chemical attenuation at day 8 post-infection. 
Having established a significant divergence in T cell behaviour at day 4 post-infection, splenic 
and intrahepatic T cells were analysed during fulminant disease at day 8 post-infection, at which 
timepoint host immunopathogenesis diverges significantly from control ECM mice. At day 8-9 
post-infection, NCM mice show a decrease, albeit not statistically significant, in their splenic 
CD8+CD44hiCD62L- T effector subset (fig 3.15). 
 
 
 
 
 
 
 
 
Figure 3.15. Animals subjected to chemical attenuation feature comparable numbers of splenic 
effector memory T cells at day 8 post-infection to infected controls. Animals (groups of 5) were 
assigned to ECM, NCM and control groups as described, NCM and ECM mice were infected with 10,000 
PbANKA sporozoites and sacrificed at day 8 post-infection. Spleens were harvested and lymphocytes 
isolated and stained for CD8, CD4, CD44 and CD62L. Whole number splenic effector memory cells: A) 
CD8+CD44hiCD62L- and B) CD4+CD44hiCD62L- were calculated. Statistics calculated by one-way 
ANOVA with Bonferonni post-hoc adjustment. Asterisks signify degrees of significance where *** 
indicates P < 0.001, ** indicates P = < 0.01, * indicates P  < 0.05 and “ns” indicates P >0.05. 
 
 
Furthermore, at day 8-9 post-infection, NCM mice show a decrease in expression of both CD69 
and CD25 activation markers in splenic CD8+ T cells and a decrease in CD69 expression on 
CD4+ T cells compared to ECM control mice (fig 3.16). 
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Figure 3.16. Animals subjected to chemical attenuation feature decreased expression of CD69 and 
CD25 on their splenic CD8+ T cells at day 8 post-infection. Animals (groups of 5) were assigned to 
ECM, NCM and control groups as described, NCM and ECM mice were infected with 10,000 PbANKA 
sporozoites and sacrificed at day 8 post-infection. Spleens were harvested and lymphocytes isolated and 
stained for CD8, CD4, CD69 and CD25. Expression of CD69 and CD25 markers by T lymphocytes 
expressed as percentage activation on A) CD8+ T cells and B) CD4+ T cells. Statistics calculated by one-
way ANOVA with Bonferonni post-hoc adjustment. Asterisks signify degrees of significance where *** 
indicates P < 0.001, ** indicates P = < 0.01, * indicates P  < 0.05 and “ns” indicates P >0.05. 
 
3.7 Flow cytometry analysis reveals a decrease in CD11c+ DCs present at the liver and 
spleen in experimental animals subjected to chemical attenuation at day 8 post-infection 
T cell activation in ECM occurs in response to a systemic Th1 environment and antigen 
presentation by CD11c+ DCs [196, 211]. I observed a lower number of CD11chighCD8+ DCs in 
our NCM model in liver and a pronounced decrease in spleen at day 8 post-infection (fig 3.17). 
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This indicates a decreased capacity for APC-mediated T-cell priming in the NCM model, 
consistent with reduced T-cell activation and subsequent absence of cerebral pathology. 
 
Figure 3.17. Animals subjected to chemical attenuation feature decreased numbers of  
CD8+CD11c+ DCs at the liver and spleen at day 8 post-infection. Animals (groups of 5) were 
assigned to ECM, NCM and control groups as described, and infected with 10,000 PbANKA sporozoites 
and sacrificed at day 4 and day 8 post infection. Liver (i) and spleen (ii) were harvested, lymphocytes 
isolated and stained for CD8 and CD11c to determine whole number of CD8+CD11c+ DC population. 
Statistics calculated by one-way ANOVA with Bonferonni post-hoc adjustment. Asterisks signify degrees 
of significance where *** indicates P < 0.001, ** indicates P = < 0.01, * indicates P  < 0.05 and “ns” 
indicates P >0.05. 
 
3.8 Animals subjected to chemical attenuation feature a reduced cytokine cascade within 
the cerebral tissues 
HCM is characterized by elevated pro-inflammatory cytokines in the serum of infected patients 
[190, 192]. Moreover, in ECM, depletion of pro-inflammatory cytokines including IFN-γ and 
TNF-α prevents cerebral pathology in mice [153, 182, 183, 200, 228, 229, 267, 268]. 
Furthermore, IFN-γR signalling regulates the sequestration of CD8+ T cells in the brain [212]. 
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Given that NCM is characterized by a reduction in sequestered lymphocytes in the cerebral 
tissues, I measured pro-inflammatory cytokine proteins present in the whole brains of animals by 
cytokine bead array analysis. It revealed an increase in IL-17 and a decrease in IL-10, IL-6, IL-4 
and TNF-α at day 8 post-infection in the brains of mice subjected to chemical attenuation 
compared to control infected mice (fig 3.18). 
 
3.9 Adoptive transfer of splenocytes from animals subjected to chemical attenuation leads 
to 70% protection against ECM and is ablated upon depletion of CD8+ T cells 
To investigate the transferability of the early cellular immune environment in NCM, I performed 
an adoptive transfer of 2 x 107 liver-derived lymphocytes at 48 h post-sporozoite inoculation into 
naïve animals, which were challenged with 10,000 PbANKA sporozoites 24 h later. This did not 
confer any protection to recipient animals that received lymphocytes from either chemically 
attenuated animals or ECM control animals. In contrast to this, adoptive transfer of 2 x 107 
whole splenocytes from NCM donors to naïve mice caused approximately 70% protection 
against cerebral symptoms compared to 0 % protection in control animals that received 
splenocytes from ECM donor animals (fig 3.19). In order to determine the component of the 
transferred spleen lymphocyte subset responsible for protection, donor animals were depleted of 
their CD8+ T cells. Strikingly, protection could not be conferred to recipient mice if donor NCM 
mice were depleted of CD8+ T cells (fig 3.19). Protection could also not be conferred when 
splenocytes from uninfected animals were transferred. This indicates that NCM protection bears 
an essential requirement for CD8+ T cells, as part of a systemic modulation of the early host 
immune response. 
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Figure 3.18. Mice subjected to chemical attenuation show decreased IFN-γ , IL-6, IL-4 and TNF-
α  and elevated IL-17 in ex vivo  brain tissue at day 8 post-infection. Animals were subjected to 
chemical attenuation, sacrificed at day 8 post-infection and their brains were harvested assessed by 
cytokine bead array analysis. Statistics calculated by one-way ANOVA with Bonferonni post-hoc 
adjustment. Asterisks signify degrees of significance where *** indicates P < 0.001, ** indicates P = < 
0.01, * indicates P  < 0.05 and “ns” indicates P >0.05. 
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Figure 3.19. The NCM phenotype can be adoptively transferred to naïve recipient mice via 
splenocyte transfer, is abrogated upon depletion of CD8+ T cells. Animals (groups of 5) were 
assigned to ECM, NCM and control groups as described, NCM and ECM mice were infected either 
depleted or not for CD8+ T cells, infected with 10,000 Pb ANKA sporozoites and sacrificed at day 2 
post-infection. Splenic lymphocytes from the depleted and undepleted donor groups were isolated, 
pooled and adoptively transferred into recipient mice (n=5).  
 
Flow cytometric analysis of the adoptively transferred cells revealed that mice subjected to 
chemical attenuation have fewer CD4+ and CD8+ T cells present in the spleen at day 2 post-
infection compared to uninfected mice. (fig 3.20).   
 
3.10 Protection arising from chemical attenuation depends upon IL-10 
Given the apparent downregulation of the Th1 response during fulminant infection in 
chemically-attenuated mice, I investigated the role of the anti-inflammatory cytokine IL-10. IL-
10 is a master regulator of immunity to malaria and is important in ECM immunopathology, in 
which it is responsible for mitigating Th1 responses [269, 270]. Given the NCM paradigm, in 
which stronger pro-inflammatory responses occur at earlier timepoints, compared to ECM, and 
subsequently decrease at later infection, it seemed appropriate to investigate the role of IL-10 in 
the NCM model. IL-10tm1Cgrn knockout mice and WT mice treated with anti-IL-10 receptor 
antibody were subjected to to chemical attenuation and subsequently challenged with 10,000 
PbANKA sporozoites. Both depleted and IL-10 -/- animals developed ECM pathology and died 
at 
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Figure 3.20. Constituent cell subsets in adoptive transfer of 2 x 107 splenocytes from NCM mice 
sacrificed at day 2 post-infection. Animals (groups of 5) were assigned to NCM and control groups as 
described, and infected with 10,000 PbANKA sporozoites and sacrificed at day 2 post infection. Spleens 
were harvested, lymphocytes isolated and stained for CD8, CD4, CD44 and CD62L. Numbers were 
normalized to the 2 x 107  shot. Statistics calculated by one-way ANOVA with Bonferonni post-hoc 
adjustment. Asterisks signify degrees of significance where *** indicates P < 0.001, ** indicates P = < 
0.01, * indicates P  < 0.05 and “ns” indicates P >0.05. 
 
days 10-12, indicating the absolute requirement of IL-10 to the NCM phentotype (fig 3.21). I 
next injected mice subjected to chemical attnuation with IL-10-receptor antibody at day 5 post-
infection, and protection was still abrogated, with all mice succumbing to ECM (fig 3.21). This 
suggests that the protective role of IL-10 in NCM is stage-specific and mediated from the later 
stages, not the pre-erythrocytic stage. 
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Figure 3.21. The NCM phenotype mediated by IL-10 at fulminant infection. First panel: Animals 
(groups of 5) were assigned to ECM, NCM and control groups as described. IL-10tm1Cgrn knockout mice 
were subjected to NCM chemical attenuation, infected with 10,000 PbANKA sporozoites and survival 
tracked. Second panel: NCM mice were depleted of IL-10 via injection of anti-IL-10 receptor antibody 
intraperitoneally (i.p.) at either day 0 or day 5 post-infection and compared with control mice, infected 
with 10,000 PbANKA sporozoites and survival tracked.  
 
3.11 Protection arising from chemical attenuation is independent of CD25   
Since regulatory T cells are associated with the production of IL-10 and the limitation of 
inflammatory pathology [271] and have been associated with protection from ECM [242] I 
speculated that they may be responsible for the production of IL-10 or otherwise mediate T cell 
responses in the NCM model. However, depletion of CD25 had no effect on the protective 
phenotype (fig 3.22).  
 
 
 
 
 
 
 
 
Figure 3.22. Depletion of CD25 in mice subjected to chemical attenuation does not alter the 
NCM phenotype. Mice subjected to chemical attenuation (n=4) were depleted of CD25 via injection of 
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anti-CD25 antibody i.p. 7 days before infection with 10,000 PbANKA sporozoites (NCM α-CD25) and 
survival tracked in comparison to undepleted mice subjected to chemically attenuation (NCM)
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Chapter 4 
Discussion 
One of the primary complications and causes of mortality in malaria infection is cerebral malaria 
(HCM), causing up to 500,000 annual fatalities [128], mostly in older children who have already 
experienced previous malaria episodes [272]. HCM is also a significant risk factor to nonimmune 
travellers to malaria-endemic regions, who are at a very high risk of developing HCM and 
systemic shock upon first infection, possibly due to cross-reactivity of primed T cells [137]. 
Where applied, current antimalarial drug therapies are inadequately managing the cerebral malaria 
phenomenon, with a failure rate of 15-20% [130, 133]. This is not only due to the lack of medical 
infrastructure caused by the economic and social debilitation of sub-Saharan Africa, although this 
is an integral exacerbating factor [23]. Indeed, practical considerations apply, with the life cycle 
and immunopathogenesis of Plasmodium contributing to the death toll. DeSouza and colleagues 
identified two major causes of the high mortality and low success rate of interventions for HCM 
[133]: 
 
1. The immunopathogenesis of HCM is poorly characterized.   
2. The presentation of HCM symptoms, and hence diagnosis, occur a relatively short time 
before fatality. 
 
The poor characterization of HCM is mostly due to ethical and practical restrictions posed by 
working with disease models in humans. Post-mortems are often not performed on patients who 
succumb to disease, or are otherwise resisted by the family of the deceased [273]. In the absence 
of post-mortem, failure rate in cerebral malaria diagnosis is very high [135] and atypical 
presentation of cerebral malaria in the absence of parasite sequestration is not uncommon [131]. 
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Moreover, cerebral pathology causes a complicated series of events, both spatially and 
temporally, involving interaction between both parasite and host immune system. Dissecting the 
precise mechanisms that cause pathology on the molecular level would require a level of 
experimental intervention that is impossible in humans and, as a result, data within the literature 
is largely descriptive [133].  
 
Thus, considering how cerebral immunopathogenesis has such a complicated and multifaceted 
causality it is impossible to replicate the syndrome via in vitro studies. Animal models are the only 
logical means by which the interrelated components of immunopathogensis can be elucidated. 
The advantage of using an inbred mouse model is that immune responses and disease 
pathologies are generally uniform. The C57BL/6 mouse strain has a distinct Th1 bias [226] 
which renders it susceptible to the inflammatory immunopathogeneis of experimental cerebral 
malaria (ECM) and replicates many of the features present in HCM. Nonetheless, the model is 
imperfect: parasite strain and dosage are critical factors in determining survival or death from 
ECM, let alone specific and subtle components such as activation of specific lymphocyte 
subsets, and death typically occurs in only approximately 80 % of infected animals [274].   
 
In the classical description of ECM, the host undergoes a Th1 response involving the 
production of pro-inflammatory cytokines which commences upon infection of erythrocytes and 
their clearance in the spleen. This response involves the recruitment of innate immune cells such 
as monocytes and neutrophils and their chemotaxis to the brain microvasculature, effectively 
bypassing the liver [133, 199, 200, 275]. A diverse range of cytokines, especially the pro-
inflammatory cytokine IFN-γ, increase expression of adhesion molecules such as ICAM-1 and 
lymphocyte function-associated antigen 1 (LFA-1) [182, 189]. Dendritic cells capture and present 
antigen during the rupture and clearance of parasitized erythrocytes in the spleen. This, along 
with the overriding Th1 environment and costimulatory signals provided by adhesion molecules 
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[276], causes T lymphocytes to become activated and migrate via chemotaxis to the brain 
microvasculature. It is this adaptive response associated with T cell activation that occurs in the 
late blood-stage of malaria infection that leads to blood-brain-barrier damage and pathology.   
 
Numerous aspects of ECM immunopathogenesis during erythrocytic infection remain unknown. 
These include the antigen-specificity of lymphocytes that become activated within the spleen and 
migrate to the cerebral vessels [181], the nature of junctions that form at the parasite-
endothelium interface, the role of systemic immune events as contrasted to those in the spleen 
or brain and the role mechanisms that lead to the activation of lymphocytes, monocytes and glial 
cells [133].  
 
Two overlooked and undescribed components of cerebral immunopathogenesis are the pre-
erythrocytic and early erythrocytic stages. Typically, schematic descriptions of the events that 
lead to both HCM and ECM commence at the rupture of infected erythrocytes, the release of 
Plasmodium moities into the circulation, the clearance of infected erythrocytes from the spleen 
and the resulting uptake and presentation of antigen by dendritic cells [133, 181, 277].  
 
The liver stage is both clinically [264] and immunologically silent, but not entirely so. Immune 
responses are limited due to the unique and immune-privileged status of the liver, with 
lymphocyte responses specific to this organ characterized by reduced effector function, 
activation and increased apoptotic behaviours [66]. However, the silence that Plasmodium achieves 
during its invasion and expansion within the pre-erythrocytic stages are better described as an 
active process of stealth rather than a passive one in which the parasite simply does not do 
enough to cause attention to itself. This stealth is apparent in the parasite’s interaction with two 
integral components of the innate immune response, MYD88 and NF-κB. MYD88 is a protein 
essential for TLR and cytokine signalling. It binds to TLRs via its toll-interleukin receptor (TIR) 
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domain and mediates the activation of numerous transcription factors, including NF-κB. It is 
important in innate immune responses, including pathogen recognition and the inducton of 
inflammation [278]. The transcription factor NF-κB regulates genes associated with both innate 
and adaptive immunity. It is activated via ligation of the B and T cell receptors and upregulates 
genes associated with lymphocyte proliferation and development [279]. MYD88 and NF-κB 
come into play upon invasion of the hepatocyte by the sporozoite. As the sporozoite invades 
and traverses host hepatocytes, cell rupture causes the release of cytosol from the hepatocyte - in 
a process that is not stealthly at all - triggering MYD88 to cause NF-κB activation of the nitric 
oxide synthase pathway in hepatocytes surrounding infected ones [280]. However, the parasite 
apparently masks its steps, as those cells it traverses do not undergo NF-κB activation in vitro. It 
has been hypothesized that this downregulation of the localized response is due to shed malarial 
CSP relocating to the cell nucleus and directly inhibiting the NF-κB pathway [33, 281]. Indeed, 
studies have shown that Plasmodium CSP shed by motile sporozoites inhibits the respiratory burst 
in kupffer cells by activating a suppressive signalling cascade [282], rendering them resistant to 
Th1-mediated activation, inducing their apoptosis [33, 283].  
 
The lack of attention that the pre-erythrocytic stage has received in studies concerning cerebral 
malaria immunopathogenesis is most likely due to the clinical silence of this stage, which has, in 
the mind of many researchers, rendered it extraneous to most studies concerning cerebral 
malaria immunopathogenesis. However, the liver stage has proven to be of primary importance 
in anti-infective vaccine design and in studies generating and examining sterilizing immunity to 
malaria challenge in the form of attenuated parasite strains. Indeed, the pre-erythrocytic stage is 
considered a bottleneck in the life cycle at which point, if the parasite is successfully targeted by 
the immune system, the debilitating pathology associated with malaria disease can be avoided. 
Attenuation of the parasite by various means, such as γ-irradiation, gene-knockout of liver-stage 
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essential genes and the (prophylactic) administration of antimalarial compounds and antibiotics 
has created reproducible and sterilizing protective immune responses that are mostly cell-
mediated, rather than humoral, involving CD8+ T cells and IFN-γ. The refinement, description 
and characterization of these responses has made up a large part of the literature in the last fifty 
years and are a cornerstone in the field [284-286]. However, due to practical and safety concerns, 
the viability of directly transferring the whole-organism attenuated parasite approach to the field 
is open to question. In recent years, new forms of pre-erythrocytic attenuation have been 
published involving deletion of new essential genes in the parasite genome [287] the application 
of different antimalarial-acting compounds and antibiotics [117, 121]. Thus, the liver stage, 
although clinically silent, is of utmost pertinence in immunological studies and common thought 
within the field considers the liver stage to be of primary importance in understanding protective 
immune responses. This being so, why has it not been subject to much study in relation to ECM. 
 
There is, in fact, some limited evidence that early responses can play an immunomodulatory role 
in ECM. However, the data in these studies are generally incidental, coming about in descriptive 
studies of protective models, rather a result of deliberate experimental intervention at the early 
stages. For example, a recent study reported that a transgenic parasite line lacking a Plasmodium-
specific apicoplast protein resulted in impaired liver-stage development, attenuated merozoite 
formation, and reduced incidence of cerebral pathology [252]. Furthermore, two studies, one 
involving co-infection of PbANKA and PbK173 [236] and another involving irradiated blood 
stage parasites [251] associated early pro-inflammatory cytokine responses with protection from 
ECM. 
 
There appears to be a theme emerging: an early inflammatory response is shared between 
multiple studies concerning pre-erythrocytic immunity to malaria. This is logical, since IFN-γ is 
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an essential requirement for RAS immunity [98], GAP immunity [97] and CPS immunity [92, 
96]. Furthermore, succesive immunizations with irradiated sporozoites has been shown to 
induce IL-12 and inflammation in kupffer cells within 24 hours, thought to augment APC 
activity in the acquisition of RAS immunity [288].  
 
Thus the standard model for ECM immunopathogenesis, which commences at the point of 
erythrocyte rupture and lasts for some 5 to 10 days in a spiral of devastating immunological 
responses leading to death, is deserving of analysis at its pre-erythrocytic stages in a similar vein 
to RAS, GAP and CPS.  
 
Taking that into consideration, this work aimed to modulate the course of parasite development 
by means of applying an antimalarial compound in a manner comparable to chloroquine 
chemoprophylaxis. The project addressed two primary questions: By attenuating the parasite 
during its liver stage development, is it possible to elicit immune responses broadly comparable 
to those that occur when the parasite is subjected to attenuation by other means? If it is possible 
to provoke an immune response that causes sterilizing immunity against subsequent parasite 
infection, is it possible to provoke a response that causes modulation of ECM 
immunopathogenesis? These questions were encompassed in the two primary aims of this study, 
to:  
1.       Attenuate Plasmodium at the pre-erythrocytic stage as a means of manipulating the 
host immune response to alter the clinical outcome of ECM via sub-therapeutic 
chemoprophylaxis 
2.       Functionally characterize any pre-erythrocytic immunological responses that are 
required for protection from ECM  
To address the first point, it was necessary to select a suitable methodology to attenuate the liver 
stage. The aim of the study was to attenuate the parasite efficiently to induce a protective 
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response against cerebral pathology at its pre-erythrocytic stage, without killing the parasite 
entirely. This being so, the means of attenuation would have to target the parasite at the pre-
erythrocytic stage, but nonetheless permit it to initate blood stage infection. Furthermore, it must 
have no further pharmacological influence once blood stage replication had commenced. 
Irradiation of sporozoites at levels lower than the level customary to induce sterilizing immunity 
was considered too imprecise and unlikely to induce appropriate immune responses [49]. 
Transgenic parasite lines lacking genes involved in liver-stage maturation was considered one 
option, and numerous clonal lines of such gene-knockouts have been generated that produce 
similar non-cerebral phenotypes [252] (S Lepper PhD Thesis, F Kohlhepp PhD Thesis, Y Maier 
PhD thesis, Fernandes et al unpublished). Unfortunately, the phenotype produced by these 
transgenic lines has proven to be unstable and typically result in 30-70% protection from ECM. 
It was therefore logical to utilize CPS in the attempt to generate a 100% reproducible phenotype 
that is relatively easy to administer by means of a compound that has a long description in the 
literature. Due to the aim of the study, the compound had to be active against the parasite’s liver 
stage. 
 
Antimalarial 8-aminoquinolines were synthesized in the 1940s and include pentaquine, 
isopentaquine and primaquine [289]. They have a proven gametocidal and liver-stage activity by 
means of their active metabolites which are structually similar to naphthaquinones [289]. 
Although not fully expounded, it is thought that they may disrupt Plasmodium metabolism by the 
presence of foreign redox reagents similar to naturally occurring ubiquinone [289, 290], binding 
to DNA and inhibiting DNA polymerase [289]. I tested a number of such 8-aminoquinolines at 
varying concentrations and by various administration routes and schemes (fig 3.1, table 3.1). The 
administration of  isopentaquine at 60mg/kg by intraperitoneal injection proved to be cytotoxic 
whereas the administration of primaquine at any concentration either below 60mg/kg or by any 
means than intraperitoneal injection proved to be ineffective. The observed NCM phenotype, 
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delayed onset of blood stage parasitemia, absence of cerebral symptoms and death from 
hyperparasitemia-associated anaemia, occurred after administration of both primaquine and 
isopentaquine (fig 3.2 and 3.3). Although primaquine is the most efficacious 8-aminoquinoline, 
in terms of its success as a classical antimalarial therapy [289], the NCM phenotype that it caused 
was not as effective and required administration at a higher concentration than isopentaquine. 
Animals treated with primaquine died at parasitemias of approximately 60% at days 15-20 post-
infection, whereas animals subjected to isopentaquine treatment reached parasitemias in excess 
of 80% and survived later than day 20 post-infection,. The phenotype produced by 
isopentaquine was deemed to be superior and was utilized for all subsequent experiments.  
 
It is interesting to note that the NCM phenotype is by no means unique to isopentaquine. In a 
sense, this is pleasing, because it is further demonstration that NCM is not the result of a unique 
pharmacological interaction between drug and parasite. Indeed, in order to fulfil the criteria of 
Aim One, it was necessary to prove that the phenotype was the result of the host immune 
response rather than pharmacokinetic modulation of the parasite’s kinetics or metabolism. This 
was achieved in part by the isolation and transfer of parasitized erythrocytes from animals 
subjected to chemical attenuation into naïve animals (fig 3.8). Animals succumbed to cerebral 
pathology indicating that a) the protective effect is the result of a host response, rather than a 
modification of the parasite itself and b) the origin of the modulating effect is most likely pre-
erythrocytic. This latter point was further confirmed by the administration of parasitized 
erythrocytes to animals subjected to chemical attenuation, which were also susceptible to ECM 
(fig 3.8).  
 
A potential critique of this experiment and the conclusion drawn from it may be that the 
phenotype is the result of reduced blood stage inocula, which have been shown to induce 
protective immunity in P. falciparum by the induction of a cellular immune response [123]. 
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However, it has never been proved definitively that low parasitemia is correlated with absence of 
ECM, although one study demonstrated that older animals were less susceptible to ECM due to 
lower parasitemia [154]. Furthermore, the adoptive transfer experiment involved the harvesting 
of splenocytes at 48 hours post-infection, long before the onset of patent parasitemia (fig 3.19). 
Moreover, it could be argued that the question is somewhat redundant, given that, in nature, the 
pre-erythrocytic stage is never bypassed, rendering the question of whether the effect is due to 
attenuated liver stage development causing reduced blood stage inocula or attenuated liver stage 
development itself a moot point. Following the onset of parasitemia, the kinetics in mice 
subjected to chemical attenuation show no deviation from untreated controls, contrary to the 
low blood stage parasitemia that one would expect to see as the result of a low blood-stage 
inoculum.  
 
Nonetheless, it is my judgement that the adoptive transfer and CD8 neutralization experiments 
definitively proves that CD8+ T cells are responsible for the induction of protection, and hence 
the immune response is a pre-erythrocytic one, rather than erythrocytic (fig 3.19). Furthermore, 
these experiments demonstrate that the protective effect is immunological in origin. 
 
The modulation in the immunopathogenesis of infection in NCM was addressed by harvesting 
the animals at two key timepoints post-infection. In our experience, normal wild type PbANKA 
infection does not cause patent parasitemia until day 4 post-sporozoite-infection and animals do 
not succumb to cerebral symptoms until days 8-9 post-sporozoite-infection. Chemically 
attenuated PbANKA infection, however, induces patent parasitemia at approximately day 6 post-
sporozoite-infection and mice succumb to hyperparasitemia-associated anaemia at approximately 
day 25 post-sporozoite-infection. Thus three timepoints were envisaged for the immunological 
characterization of the NCM phenotype: days, 2, 4 and 8. Day 2 was chosen for the adoptive 
transfer experiments as a very early stage at which point liver stage parasites, even in untreated 
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infection, have not reached schizogony. This stage is firmly in the pre-erythrocytic phase during 
which one would expect innate immune responses and perhaps very early adaptive immune 
responses to malaria infection. Flow cytometric analysis of the adoptively transferred cells at day 
2 post-infection revealed that mice subjected to chemical attenuation have fewer CD4+ and 
CD8+ T cells present in the spleen at day 2 post-infection compared to uninfected mice. It is 
possible that this is because there is a significant recruitment of cells from the spleen to the liver. 
However, there was no significant difference in numbers of splenic CD8+ and CD4+ T effector 
cells at day 2 post-infection between chemically attenuated and control animals (fig 3.20). 
 Day 4 represents the timepoint that in untreated infection represents the temporal interface 
between the liver stage and blood stage. In order to draw a fair comparison between ECM and 
NCM it was necessary to select a timepoint at which blood stage infection had not yet occurred. 
This is because blood stage infection is known to have a modulating influence on liver immune 
responses [291, 292]. Also, given that it is coincident with late liver stage development and 
schizogony in untreated animals, it was selected as the principle timepoint to analyse early 
responses in NCM immunopathogenesis. Day 8 was chosen on the basis that it is the timepoint 
when susceptible mice succumb to cerebral pathology.  
 
Based on experiments at these timepoints, the data indicate that an altered early host immune 
response is indeed responsible for modulating cerebral malaria immunopathogenesis and causing 
the NCM phenotype. This early response is a pro-inflammatory, cell-mediated one with 
increased T-cell activation in liver and spleen, higher numbers of effector T cells, cytokine-
secreting T cells and proliferating, multifunctional T cells producing pro-inflammatory cytokines 
(fig 3.9, 3.11, 3.12, 3.13). Dendritic cell numbers, T-cell activation and infiltration of CD8+ T 
cells to the brain are decreased in later infection, mediated by the anti-inflammatory cytokine IL-
10 (fig 3.5, 3.15, 3.17, 3.21). Strikingly, this protection can be transferred to naïve animals by 
adoptive transfer of lymphocytes from the spleen at very early infection (fig 3.19). This data 
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suggests that a subpopulation belonging to CD8+ T cells as early as day 2 post infection are 
responsible for protection (fig 3.19).  
 
Indeed, this study uncovers a relationship in both localization and timing of anti-parasitic T-cell 
responses involved in the immunopathogenesis of ECM and a previously undescribed role for 
the pre-erythrocytic stage in malaria. Chemical attenuation induces T cell activation and increased 
Th1 multifunctionality at an earlier timepoint than it occurs in a normal ECM infection, marked 
by increased Th1 cytokine production (fig 3.10, 3.11, 3.12). Inflammation is severe in the liver 
(fig 3.9), an organ that does not normally undergo significant inflammatory pathology in the first 
days post-sporozoite inoculation in C57BL/6 mice [293]. Indeed, ECM models with unnaturally 
early IFN-γ responses have been associated with protection from ECM [236, 251], where it 
diverges from its normal role of mediating splenic T-cell activation and the development of 
pathology during the fulminant stage of disease [133].  
 
The protection in the NCM model may occur via similar dynamics to these studies, with 
attenuated pre-erythrocytic parasite development leading to increased early liver-stage T-cell 
activation associated with IFN-γ and increased Th1 responses. This unnaturally early peak leads 
to modulation of later inflammatory immunopathogenesis in the host, during the phase where 
splenic T cells would normally become activated and migrate to the brain at the crucial timepoint 
between day 8-10 post-infection (day 4-6 post-blood infection) [133]. NCM hosts display 
decreased CD11cCD8+ DC numbers, downregulation of T-cell activation, no cerebral infiltration 
and a complete absence of cerebral pathology. This downregulation is mediated by IL-10 during 
the fulminant stage of disease. CD8+ T cells, including the effector memory subset, are a 
constituent of the unnaturally early peak and I assume are largely responsible, as adoptive transfer 
of splenocytes from NCM hosts cannot confer protection to naïve animals in their absence.  
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Based on these data, I have assembled a new working hypothesis for the immunopathogenesis 
of PbANKA infection in mice subjected to chemical attenuation, leading to the NCM phenotype 
(graphical demonstration see fig 4.1) contrasted with key steps involved in ECM 
immunopathogenesis described above (section 1.8): 
 
STEP ONE: Following sporozoite invasion, chemical attenuation of the parasite causes 
prolonged pre-erythrocytic development in the liver prior to the onset of blood stage 
infection. 
Sporozoites invade hepatocytes in the same process as with untreated sporozoites. The presence 
of isopentaquine within the serum causes a cytotoxic effect against the developing parasite. This 
effect, like the activity of the majority of 4-aminoquinolines, is not well characterized. Parasite 
development is delayed and results in a stalling in the development of the parasite within the liver 
and the onset of blood stage infection. This prolonged development may be concurrent with 
hepatocyte apoptosis.  
 
STEP TWO: Attenuated development at this early time point causes an increase in T 
effector cells at the liver, increased multifunctionality and proliferation of Th1-skewed 
cells and pro-inflammatory cytokine production.  
Due to attenuated parasite growth concurrent with hepatocyte apoptosis, innate immune cells, T 
cells and dendritic cells are recruited to the liver and sample parasite antigen displayed on MHC-
I. Phagocytosis of apoptotic hepatocytes and perforin-mediated cytotoxic lysis occurs by CD8+ 
T cells, which in turn promotes the production of inflammatory cytokines and provokes a 
systemic Th1 response. Dendritic cells migrate to the draining lymph nodes that serve the liver, 
where they present antigen to T cells. 
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STEP THREE: Activated, Th1-skewed T cells migrate to the spleen where there is an 
associated increase in T effector cells, multi-functionality and Th1 responses prior to the 
release of merosomes and rupture of infected erythrocytes.  
Up to blood stage infection, the inflammatory response is mediated by CD8+ T cells activated 
from the liver, rather than dendritic cells.  
 
 
STEP FOUR: At the point of blood-stage infection, the delicate balance required for 
ECM immunopathology is disrupted. Rupture of infected erythrocytes occurs as the 
early splenic pro-inflammatory response is in the process of being brought under control 
by emerging Th2 responses, mediated by IL-10.  
Overriding systemic inflammation provokes the production of IL-10. This reduces the systemic 
Th1 response, dampens CD8+ T cell activation and proliferation and downregulates the 
expression of adhesion molecules on the vascular endothelium. As blood stage parasites undergo 
schizogny and blood stage infection is established, clearance of parasitized erythrocytes in the 
spleen and the release of parasite moieties by ruptured erythrocytes causes the sampling of 
parasite antigen by dendritic cells. These present antigen but to reduced effect compared to 
control animals, since the host’s Th1 response, concomitant with CD8+ T cell activation and 
prodigious concentrations of pro-inflammatory cytokines, is already being brought under 
control.   
 
STEP FIVE: Reduced numbers of CD8+CD11c+ dendritic cells in the spleen are 
associated with decreased phagocytosis of parasite moieties which in turn leads to 
decreased priming of lymphocytes.  
The onset of fulminant infection does not provoke the Th1 response as occurs in control 
animals, and this is associated with a reduced number of splenic CD8+CD11c+ cells. Reduced 
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antigen presentation causes a signficant reduction in splenic T cell priming and numbers of 
CD8+ T effector cells in the spleen at fulminant infection are reduced.  
 
STEP SIX: Systemic inflammation is reduced at the fulminant stage of infection, 
mediated by IL-10, leading to reduced endothelial cell activation in the brain, reduced 
binding of infected erythrocytes to endothelial receptors and reduced migration of 
lymphocytes from the spleen to the brain microvasculature. 
The critical and integral cause of ECM pathology is the migration of CD8+ T cells, once 
activated, to the brain microvasculature by chemotaxis. Reduced systemic inflammation is 
associated with reduction in the production of chemokines, reduced priming and activation of 
CD8+ T cells within the spleen causes a reduction in numbers of cells that migrate to the brain. 
 
STEP SEVEN: This in turn reduces leukocyte and parasite sequestration and prevents 
damage to the blood-brain barrier and associated cerebral pathology. 
The brain microvasculature in protected animals remains undamaged by histopathological analysis 
and levels of leukocyte sequestration remain comparable to naïve animals. Blood infection is still 
present and undiminished, and as a consequence animals become anaemic and die at parasitemias 
>80%. 
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Figure 4.1. A hypothetical schema detailing how chemical attenuation affects 
immunopathogenesis of mice infected with PbANKA sporozoites (compiled from the data 
within this thesis and adaption of Renia et al 2006 and deSouza et al 2010 [181] [133]).  
A) Chemical attenuation leads to NCM outcome. Following sporozoite invasion, chemical attenuation of 
the parasite causes prolonged pre-erythrocytic development in the liver prior to the onset of blood stage 
infection. Attenuated development at this early time point causes an increase in T effector cells at the 
liver, increased multifunctionality and proliferation of Th1-skewed cells and pro-inflammatory cytokine 
production. These activated, Th1-skewed T cells migrate to the spleen where there is an associated 
increase in T effector cells, multi-functionality and Th1 responses prior to the release of merosomes and 
rupture of infected erythrocytes. At the point of blood-stage infection, the delicate balance required for 
ECM immunopathology is disrupted. Rupture of infected erythrocytes occurs as the early splenic pro-
inflammatory response is in the process of being brought under control by emerging Th2 responses, 
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mediated by IL-10. Reduced numbers of CD8+CD11c+ dendritic cells in the spleen are associated with 
decreased phagocytosis of parasite moieties which in turn leads to decreased priming of lymphocytes. 
Systemic inflammation is therefore reduced at the fulminant stage of infection, mediated by IL-10, 
leading to reduced endothelial cell activation in the brain, reduced binding of infected erythrocytes to 
endothelial receptors and reduced migration of lymphocytes from the spleen to the brain 
microvasculature. This in turn reduces leukocyte and parasite sequestration and prevents damage to the 
blood-brain barrier and associated cerebral pathology.  
B) Absence of chemical attenuation leads to ECM outcome. Following sporozoite invasion, parasites 
undergo pre-erythrocytic development in the liver prior to the onset of blood stage infection. No 
significant protective pro-inflammatory response occurs at either liver or spleen at the pre-erythrocytic 
stage. At blood stage infection, increasing blood stage parasitemia and rupture of infected erythrocytes is 
associated with phagocytosis of parasite moieties by splenic CD8+CD11c+ dendritic cells, which 
exogenously process antigen via MHCI, prime and activate lymphocytes and cause systemic 
inflammation, associated with pro-inflammatory cytokines such as IFN-γ. Systemic inflammation 
increases endothelial activation in the brain, increased binding of infected erythrocytes to endothelial 
receptors and increased migration of lymphocytes from the spleen to the brain microvasculature in 
response to chemokines. This leukocyte and parasite sequestration damages the blood-brain barrier and 
leads to cerebral pathology, possibly through antigen-specific T cell cytotoxicity, via MHCI restricted 
presentation of parasite-derived antigen on endothelial cells; hemorrhaging, coma and death results.  
 
Examination of the T cell activation markers at day 4 post-infection revealed an expression 
pattern that, on first examination, appears to be contradictory. Whereas mice subjected to 
chemical attenuation featured higher numbers of splenic CD44hiCD62L- effector T cells relative 
to control ECM mice (fig 3.11), they featured decreased expression of splenic CD69 and CD25 
activation markers (fig 3.14). However this is not unexpected, since both CD69 and CD25 are 
very early activation markers [251, 266]. I hypothesize that at day 4 post-infection in control 
ECM animals, blood stage infection has just commenced and DCs initiate the presentation of 
antigen to T cells, triggering their activation, and upregulation of CD69 and CD25 on the cell 
surface. This is in contrast to mice subjected to chemical attenuation, which become activated 
earlier due to prolonged antigen presentation at the liver and/or hepatocyte apoptosis, and 
whose T cells have become fully differentiated into the T effector subset by day 4 post-infection, 
concomitant with the increased Th1 response. It is unsurprising that there is no significant 
difference in the expression of CD25 and CD69 in the liver at day 4 post-infection between 
NCM animals and ECM controls, since the liver is unlikely to be a site of antigen presentation or 
T cell activation during normal PbANKA immunopathogenesis. In chemically attenuated 
animals, the liver already features an abundance of T effector cells by day 4 post-infection, 
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whose activation is complete, hence there is no significant difference between the number of 
CD69 and CD25 cells in the organ at this timepoint.  
Some experimental ECM models with unnaturally early IFN-γ responses have been associated 
with protection from ECM [236, 251], where inflammatory responses may diverge from their 
normal role of mediating splenic T cell activation and the development of pathology during the 
fulminant stage of disease [133]. I hypothesize that chemical attenuation in the NCM model 
causes protection via similar dynamics (fig 4.1). Attenuated pre-erythrocytic parasite 
development induces T-cell activation, increased Th1 cytokine production and increased Th1 
multifunctionality at an earlier timepoint than in a normal ECM infection. This early peak leads 
to modulation of later inflammatory immunopathogenesis in the host, during the phase where 
splenic T cells would normally become activated and migrate to the brain at the crucial timepoint 
between day 8-10 post-infection (day 4-6 post-blood infection) [133]. 
 
It is of interest that the data indicate the principle mediators of early protection from cerebral 
malaria in the NCM model to be IFN-γ producing CD8+ T cells. These cells, although classically 
associated with the adaptive immune response, can produce nonclonally restricted IFN-γ under 
numerous conditions, such as bacterial infections [236, 248-250]. Lertmemongkolchai and 
colleagues suggest that rapid CD8+ T cell activation in this manner may be a component of 
innate immunity to intracellular pathogens, possibly due to cytokine-mediated bystander events 
as opposed to engagement of the TCR [250]. An alternative explanation in the literature is that 
early IFN-γ may be produced by a minor population of CD8+ T cells of nonclassical ontogeny 
expressing similar markers to CD8+ T cells [236, 294, 295]. Our results are in accordance with 
the study by Mitchell et al which found the source of IFN-γ to be CD8+ T cell derived, rather 
than NK derived as in previous models, which the authors attributed to “study differences or the 
occurrence of idiosyncratic processes in vitro” [236]. NK cells, innate cytotoxic lymphocytes, 
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bridge the gap between the innate and adaptive response [33] and play an important role in 
susceptibility. Indeed, NK cells are early producers of IFN-γ and this cytokine has been 
associated with spontaneously resolving infection in numerous Plasmodium species [80]. 
Conversely, lethal infection has been associated with the absence of NK-produced IFN-γ [80].  
 
The question of the epitope specificity of these CD8+ T cells is therefore an open one. The 
antigen-specificity of T cells that migrate to the brain in ECM is still unknown and little is 
known in general about antigen-specific T cells in malaria infection [296]. It is conceivable that 
CD8+ T-cell mediated protection leading to NCM is not restricted to any one particular antigen. 
Indeed, it is possible that early T cell priming, regardless of antigen, causes a more generalized 
systemic downregulation of the Th1 response, antigen-presentation and T cell activation where 
and when it matters, at the onset of fulminant disease. Nonetheless, I hypothesize that protective 
T cells in NCM are specific to pre-erythrocytic parasite antigen and that a shared antigenic 
repertoire may exist between the parasitized hepatocyte and the infected erythrocyte and is 
displayed via MHCI on the cytokine-activated brain endothelial cell [181]. The induction of rapid 
parasite-specific T cell responses to malaria infection is not a novel concept, since it has been 
previously demonstrated that antigen-specific adaptive T cell responses occur rapidly in response 
to RAS immunization less than eight hours after infection [297]. Indeed, T cells from transgenic 
mice bearing CSP-specific TCRs are able to differentiate from naïve to effector function, 
including cytotoxic activity, parasite-killing capacity and the production of IFN-γ, within merely 
24 hours of infection [298]. The development of T effector populations in NCM protection at 
the much later timepoint of 4 days post-infection protection is therefore unsurprising.  
 
Rapid T cell activation obviously necessitates very fast DC activation and uptake of foreign 
antigen. Although no significant difference was observed between NCM and ECM groups at day 
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4 post-infection, this is consistent with DC migratory behaviour. The time between antigen 
phagocytosis and egress from the liver is only one hour [299]. Analysis of those DCs presenting 
in the liver-draining lymph nodes may provide further data regarding antigen presentation in the 
NCM model. Furthermore, it is possible that isopentaquine treatment enhances antigen uptake 
due to the induction of apoptosis in infected hepatocytes. RAS immunization has been shown to 
induce DC antigen uptake in a similar manner and may enhance the immune response [300].  
 
However, my observation of a decreased number of DCs in animals subjected to chemical 
attenuation at day 8 post-infection is consistent with reduced T-cell activation at the fulminant 
stage of infection, a component of the overall downregulation in Th1 responses. The connection 
between CD11chiCD8+ DCs and ECM is well established. Parasites associate with these DCs, 
which capture dying cells and exogenously process antigen for cross-presentation via MHCI 
[197]. They have been shown to prime naïve CD8+ T-cell proliferation and cytotoxic T 
lymphocyte (CTL) effector functions [209] with the induction of specific CD8+ T-cell responses 
abrogated in their absence [301]. Recent work indicates that it is the CD11chighCD8+ DCs that are 
responsible for ECM immunopathogenesis [196]. Chemically attenuated NCM hosts display 
decreased CD11chiCD8+ DC numbers which in turn downregulates T-cell activation, resulting in 
the absence of cerebral infiltration and a complete absence of cerebral pathology. 
 
This downregulation is mediated by the anti-inflammatory cytokine IL-10 during the fulminant 
stage of disease in a response that I hypothesize represents the host bringing its early pro-
inflammatory response under control at the stage where T cell priming and/or chemotaxis to the 
brain would occur. IL-10 plays an essential role in ECM immunopathology that can both inhibit 
pathogen clearance and decrease immunopathology [269, 270]. Furthermore, it has been 
demonstrated that neutralization of IL-10 leads to ECM symptoms in otherwise resistant mice 
[184]. Since regulatory T cells are associated with the production of IL-10 and the limitation of 
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inflammatory pathology [271] and have been associated with protection from ECM [242] I 
speculated that they may be responsible for the production of IL-10 in the NCM model or 
otherwise mediate T cell responses. However, depletion of CD25 had no effect on the protective 
phenotype (fig 3.22). The source of IL-10 therefore remains unknown, though recent literature 
reports an IL-10 producing CD4+CD25-Foxp3- regulatory T cell subset associated with the 
modulation of pathology in P. yoelli  [302, 303]. 
 
This work has larger implications in dissecting the immunological basis of HCM pathology, a 
complex sequence of inter-related events thought to begin with pRBC sequestration or rupture 
[133]. These data do indeed suggest a role for the early intrahepatic host immune responses that 
can alter the course of downstream systemic immunopathogenesis as outlined in the working 
hypothesis for NCM immunopathogenesis above.  
 
Liver tolerance may explain why such potentially protective pre-erythrocytic responses do not 
naturally occur in HCM: The liver is served by the hepatic portal vein as its main blood source, 
and this vein delivers blood from the gut, consisting of various endotoxins, bacterial products 
and food antigens [66]. This continuous presence of non-self commensal antigens places 
restrictions on the activation and effector function of T cell responses in the liver, and for this 
reason, immune responses to infections such as malaria are controlled [39].  
 
Children do not develop HCM on first infection and older children, who have suffered multiple 
infections before, are at a higher risk of succumbing [272]. This is likely due to a memory-cell 
triggered adaptive inflammatory immune response during the erythrocytic phase [133]. 
Artavanis-Tsakonas and colleagues hypothesize that first infection of an infant living in an 
endemic area induces the innate immune response to produce only low levels of both IFN-γ and 
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TNF-α because T cells have not been primed to parasite-specific antigen. The authors suggest 
that clinical symptoms are minimal due to maternal antibody, cytokine-mediated killing or due to 
physiological barriers, such as dietry deficiencies. However, the authors hypothesize that upon 
subsequent infection, primed T cells produce increased IFN-γ leading to HCM and systemic 
shock [137]. In light of the data contained within this project, I tentatively present an alternative 
hypothesis. It is possible that first infection of children induces an early inflammatory response 
in the liver that is, relative to the response induced at the erythrocytic stage, very high and 
comparable to that observed in NCM, either antigen-specific or due to bystander CD8+ 
activation as described by Lertmemongkolchai et al [250]. This may lead to downregulation of 
the inflammatory response at fulminant infection. Upon subsequent infection, the early liver 
response retains its tolerance and is therefore much lower in comparison to the spleen-localized 
adaptive immune response at erythrocytic infection, which has now acquired the full force of a 
secondary immune response. This counteracts any downstream downregulation of fulminant 
inflammation due to early pre-erythrocytic inflammation. 
 
These data may also provide a mechanistic basis for the decrease in severe pathology observed in 
the RTS,S malaria vaccination trials and other pre-erythrocytic malaria interventions. RTS,S does 
not cause sterilizing immunity but rather causes patent but non-severe malaria, with an absence 
of cerebral malaria, possibly due to attenuated liver stage development and impaired merozoite 
release [304-306]. This end result – tolerated patency - is comparable to the erythrocytic tolerance 
due to TLR-signalling refractoriness that occurs in individuals exposed to multiple infections 
who live in endemic areas [307]. Due to ethical and practical constraints, it would be difficult to 
demonstrate this in humans. 
 
Nonetheless, within the animal model, the work contained within this project could be expanded 
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in various ways. Since it has been demonstrated that DCs can phagocytose antigen and egress 
from the liver within one hour [299] and T cells can differentiate within 24 hours post-infection 
[298] it would be of interest to elucidate DC and T cell migratory behaviour in the first 24 hours 
post-infection. Indeed, an ideal analysis would consist of a thorough determination of DC, T cell 
and systemic cytokine behaviours on a day-by-day basis throughout the course of infection from 
day 0 to 12 post-infection to determine T cell activation, differentiation and activity. It would be 
of interest to study the precise requirements and pathways for T cell activation in NCM by 
disrupting the signals mediated by key molecules such as CD45, ICOS and IL-12R by subjecting 
transgenic knockout mice lacking these molecules to chemical attenuation. Furthermore it would 
be of interest to disrupt key effector functions in cytotoxic T cells, such as perforin and 
granzymes. 
 
An ambitious potential further experiment would be to determine the epitope specificity of the 
CD8+ T cells involved in NCM phenotype and to establish whether this specificity is maintained 
from liver infection to fulminant infection and if it is shared between liver and spleen. I 
hypothesize that antigens specific to MSP-1 are a good candidate for conserved epitope 
specificity in NCM since MSP-1 is expressed in both the liver and blood stage [308]. This could 
be achieved by utilizing MSP-1 specific peptide-MHC-I tetramers using MSP-1 CD8+ T cell 
epitopes identified by computational prediction tools with the capacity to bind MHC-I in 
C57BL/6 mice [309]. Antigen-specific T cells can be detected and characterized by flow 
cytometry of tetravalent complexes consisting of multimers of four biotinylated peptide/MHC 
complexes displayed on streptavidin. This technology could determine which antigen-specific T 
cells undergo priming, expansion and differentiation in NCM, which organs they are localized to 
and when they migrate there. T cell migration in NCM could be particularly interesting to 
research, to determine the relative contribution of the spleen and liver in the protective 
phenotype. Upon demonstration that NCM is caused by antigen-specific CD8+ T cells, their 
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thresholds, kinetics and differentiation into memory phenotypes could be ascertained and 
contrasted to natural infection.  
 
Finally, it would be of interest to study the contribution, if any, of other cell types of both the 
innate and adaptive immune system, such as CD4+ T cells, NK cells or NKT cells, on the NCM 
phenotype. I am particularly interested in attributing responsibility for the production of IL-10, 
which is a crucial requirement for NCM protection. Since I have excluded CD25+ cells, it is 
possible that IL-10 produced by Tr1 or adaptive regulatory T cells may moderate the 
immunopathogenesis of disease. Examination of CD25, Foxp3 and IL-10 mRNA within the 
CD4+ T cells of animals subjected to chemical attenuation may give an indication as to the 
specific cell type producing IL-10. Due to the idiosyncratic expression pattern of such a cell type, 
it could be that this cell type cannot be neutralized via a neutralizing antibody. Therefore, upon 
identification of a likely candidate, this cell type could be separated by flow cytometry or 
magnetic cell sorting in animals subjected to chemical attenuation from both wild type and IL-10 
knockout genetic backgrounds. At this point, the purified cells could be adoptively transferred 
into infected but non-chemically attenuated mice and chemically attenuated IL-10 knockout 
mice. If the cell type isolated from wild type mice, but not IL-10 knockout mice, is able to 
induce protection in both chemically attenuated IL-10 knockout animals and infected wild type 
animals, this would provide very strong evidence that this cell type is responsible for the 
protective IL-10 in NCM. 
 
In conclusion, this work has larger implications in dissecting the complex sequence of inter-
related events that form the immunological basis of HCM pathology and presents an insight into 
the potential role of the pre-erythrocytic response in tempering downstream cerebral 
immunopathogenesis. Artavanis-Tsakonas and colleagues wrote of the Th1 immune response to 
malaria: 
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“Th1 celllular responses are required for parasite clearance, but need to be induced in a controlled, site- or organ-
specific manner in order to avoid systemic disease” [137]. 
 
 The data described herein support this statement, with the added proviso that in addition to 
organ specificity, temporal specificity of the Th1 response is also of paramount importance. The 
incorporation of these principles into future malaria prevention strategies is an endeavour well 
worth pursuing. Immuno-modulatory therapies that are able to provoke a temporally and 
physically specific Th1 response may serve to be an effective adjunctive therapy to antimalarials 
and/or vaccines in the effective management of the malaria pandemic.   
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Chapter 5 
Appendicies 
Label Score Description Score Description 
Coordination   
Gait  0–2  (none – ataxic – normal) 
Balance   0–2 (no body extension – extends front feet on wall – entire body lift) 
Exploratory Behavior   
Motor Performance  0–2 
(none – 2–3 corners explored in 90 seconds – explores 4 corners in 15 
seconds) 
Strength and Tone   
Body Position  0–2 (on side – hunched – full extension) 
Limb Strength  0–2 
(hypotonic, no grasp – weak pull-back[front paw grasp only] – strong 
pull-back) 
Reflexes and Self-
Preservation   
Touch Escape  0–2 (none – unilateral – instant and bilateral; in 3 attempts) 
Pinna Reflex  0–2 (none – unilateral – instant and bilateral; in 3 attempts) 
Toe Pinch  0–2 (none – unilateral – instant and bilateral; in 3 attempts) 
Aggression  0–2 
(none – bite attempt with tail cut – bite attempt prior to tail cut, in 5 
seconds 
Hygiene-Related 
Behavior   
Grooming  0–2 
(ruffled, with swaths of hair out of place – dusty/piloerection – normal 
with sheen) 
 
Appendix 1: The Rapid Murine Coma and Behavior Scale (RMCBS) as outlined in Carrol et al 2010. 
The scale consists of 10 parameters, each scored from 0 to 2. 0 = lowest function, 2 = highest. An 
accumulative score of 0 to 20 is obtained per animal.  
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Appendix 2: Schema depicting the administration of isopentaquine and sporozoites that leads to 
NCM outcome. 30mg/kg isopentaquine was administered three times subcutaneous injection at 24 hour 
intervals. One hour after the third administration, 10,000 PbANKA salivary gland sporozoites were 
inoculated intravenously. 
 
 
Appendix 3: Structural formulas of 8-aminoquinoline compounds used in this work. (Primaquine 
structure taken from Wikimedia Commons). Compounds synthesized by Melanie Diegel, University of 
Wuerzburg, and Eleonora Paulsen, University of Copenhagen. 
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Appendix 4: Gating strategy for multifunctional T cells. Cells were stained for CD8, CD4, IFN-γ, 
TNF-α and IL-2. CD8 (A) or CD4 (B) versus width of SSC was used to exclude doublets. Additionally 
CD8 versus CD4 was used to determine an accurate CD8 (A) and CD4 (B) positive cell population, 
excluding autofluorescent cells. IFN-γ positive cells (I) were gated and assessed for their multifunctionality 
by co-expression of TNF-α and IL-2 (II), represented by percentage according to whether they express 
one (IFN-γ), two (IFN-γ and TNF-α or IL-2) or three (IFN-γ, TNF-α and IL-2) cytokines, visualized 
within a pie chart. Analysis performed by Jochen Behrends, Research Institute Borstel. 
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B 
 
Appendix 5: Gating strategy for effector T cells. Cells were stained for CD8, CD4, CD44 and CD63L. 
Lymphocyte populations were gated in the FSC vs SSC scatter plot and FSC vs CD8 (A) or CD4 (B) was 
used to  determine an accurate CD8 (A) and CD4 (B) positive cell populations. CD8 or CD4 cells were 
gated and single and co-expression of CD62L and CD44 was determined to distinguish between specific 
cell phenotypes, which were isolated by a quadrat in a CD44 vs CD62L scatter plot. 
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Appendix 6: Gating strategy for CD11c+ dendritic cells [310]. Cells were stained for CD8 and CD11c. 
FSC-high and SSC-high cells were gated in the FSC vs. SSC scatter plot and used to determine an accurate 
CD8 and CD11c co-expressing cell populations. Example shown is an uninfected control. 
 
 
A 
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B  
 
Appendix 7: Gating strategy for CD69+ and CD25+ CD4 and CD8 Lymphocytes Cells were stained 
for CD8 (A), CD4 (B), CD25 and CD69. Lymphocyte populations were gated in the FSC vs SSC scatter 
plot and FSC vs CD8 (A) or CD4 (B) was used to determine an accurate CD8 (A) and CD4 (B) positive 
cell populations. CD8 or CD4 cells were expression of CD25 or CD69 was determined, relative to a 
negative unstained control. Examples shown are uninfected controls. 
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A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
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Appendix 8: Gating strategy for CD69+ and CD25+ CD4 and CD8 Lymphocytes Cells were stained 
for CD8 (A), CD4 (B), IL-2, IFN-γ and TNF-α. Lymphocyte populations were gated in the FSC vs SSC 
scatter plot and FSC vs CD8 (A) or CD4 (B) was used to to determine an accurate CD8 (A) and CD4 (B) 
positive cell populations. CD8 or CD4 cells were expression of IL-2, IFN-γ and TNF-α. was determined, 
relative to a negative unstained control. Examples shown are negative controls. 
 
 
 
 
Appendix 9: Gating strategy for ex vivo  NK and IFN-γ-producing NK cells. Cells were stained for 
NK1.1 and CD3. Lymphocyte populations were gated in the FSC vs. SSC scatter plot and CD3 vs NK1.1 
was used to determine an accurate NK1.1 positive and CD3 negative cell population (NK cells, contrasted 
to NK1.1 positive and CD3 positive NKT cells). Gated cells were analysed for expression of IFN-γ 
relative to a negative unstained control. Example shown is from a negative control. 
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